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Abstract 
The role of PTPA in the biogenesis of PP2A in mammalian cells 
Protein phosphatase 2A (PP2A) is an essential intracellular serine/threonine phosphatase and 
a prime example of phosphatase multisubunit architecture. The PP2A holoenzyme is a 
heterotrimer built up by a well-conserved catalytic subunit, a scaffolding subunit and one 
member out of a family of regulatory subunits, which determines the substrate specificity, 
(sub) cellular localization and catalytic activity of the PP2A.   
An activated monomer of the catalytic subunit would be unspecific and thus constitute a risk 
for the cell. In a previous study in yeast, it was shown that the catalytic subunit of PP2A is 
produced as a low active precursor that is activated by the protein Rrd (Rapamycin Resistant 
Deletion). Loss of RRD in yeast produced an unstable and metal-dependent form of PP2A 
with decreased enzymatic activity. 
Activation of PP2A by RRD is tightly linked to PP2A holoenzyme formation, thus providing 
a mechanism to prevent free and active catalytic subunit from harming the cell (Fellner et al., 
2003). This mechanism has only been shown in yeast and direct evidence for the same 
mechanism in mammalian cells is still missing. 
However, complementation and RNA-interference experiments showed that PTPA (PP2A 
Phosphatase Activator), the mammalian homologue of Rrd fulfils an essential function in the 
regulation of PP2A, which is conserved from yeast to man. 
The subject of this work was therefore to elucidate the role of PTPA in the biogenesis of 
PP2A in a mammalian cell culture system by inducible RNAi-mediated suppression of PTPA 
expression. Since it was hypothesized that decreased PP2A activity plays a role in the 
pathogenesis of Alzheimer disease, we chose neuroblastoma cell lines as experimental model 
system to establish a tetracycline-inducible knock-down of PTPA.  
Summarizing my results, I designed and cloned two novel shRNA sequences targeting the 
3´UTR of PTPA and was able to show potent knock-down of PTPA using these sequences. 
Additionally, corresponding mismatch sequences were designed and cloned to be used as 
control shRNA sequences. Also, cDNA of PTPA insensitive to shRNA was cloned to be used 
for complementation experiments. 
Over time three PTPA knock-down clones lost their ability to suppress PTPA expression, we 
analyzed the possible reason for this, in order to avoid recurrence of this phenomenon: 
I could demonstrate that the parental cell line -used in this study showed low inducibility and 
high leaky expression in comparison to other tetracycline repressor-expressing cell lines. 
After establishing a method for the detection for tetracycline in FCS (Fetal Calf Serum), I 
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could show that the FCS, used for the generation of the PTPA-knock-down clones, contained 
10
-10
g/ml tetracycline.  
Taken together, promoter leakiness, tetracycline contaminated FCS, possible apoptotic effects 
of PTPA suppression and hence counter-selection against it could contributed to the loss of 
inducible PTPA suppression over time and explain the difficulties we faced in the 
establishment of stable PTPA knock-down cell lines. 
However, after using approved tetracycline-free FCS, I was able to establish and characterize 
several PTPA knock-down cell lines in terms of cell proliferation, PP2A complex formation 
and activity of PP2A heterotrimers. Proliferation of these cell lines was only slightly affected 
by induction of PTPA knock-down. Moreover I observed that PP2A complex formation was 
not affected and enzymatic activity of PP2A towards serine-/threonine phosphorylated 
substrates was not reduced. However, this could be due to the fact that the PTPA protein 
levels were only reduced to about 50%.  
In conclusion, further investigation beyond the limited timeframe of a diploma thesis, using 
other model systems and/or a potent and stable repression of PTPA are surely justified, 
considering the overwhelming importance of fully functional and tightly regulated PP2A for 
eukaryotic cells. 
 
The role of PP2A regulatory subunit Bα in differentiation of neuronal cells 
PP2A is built up by three different subunits, a catalytic, a structural and one out of many 
regulatory subunits. The regulatory B-type subunit is chosen out of a family consisting of four 
different members: Bα, Bβ, Bγ and Bδ. Unlike the Bβ and Bγ subunits, which exhibit a highly 
regulated spatiotemporal expression pattern, Bα is ubiquitously expressed during 
development and in the adult. Bα-containing PP2A heterotrimers are therefore considered to 
possess mainly “housekeeping” functions. 
Interestingly, it was found that down regulation of Bα-containing PP2A heterotrimers is 
associated with Alzheimer´s Disease (AD)-affected brain regions, supporting the idea of a 
specific involvement of Bα-subunit in this process (Sontag et al., 1995, 1996, 1999, 2004; 
Merrick et al., 1997; Hiraga and Tamura 2000).  
PP2A is considered to be the main phosphatase of tau, a major microtubules (MT) stabilizing 
protein. As tau-dephosphorylation is important for the stabilization of MTs, PP2A is thereby a 
critical factor in the maintainance of MT integrity. On the other hand, hyperphosphorylation 
of tau leads to the formation of neurofibrillary tangles, one of the major hallmarks in AD. 
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Additional evidence for the involvement of Bα-containing PP2A in AD came from Bα-
silencing experiments in N2a and NIH3T3 cells that resulted in significant breakdown of 
acetylated and detyrosinated MTs, which is a typical hallmark of AD (Nunbhaki-Craig et al., 
2007). 
Thus, we wanted to analyze, if the ubiquitous Bα subunit plays a role in the process of 
functional differentiation, which is dependent on microtubules-stabilization and goes beyond 
its housekeeping functions. 
Indeed, we were able to show that differentiation induced by serum-starvation or retinoic acid 
administration was significantly reduced upon RNAi-mediated knock-down of Bα subunit in 
N2a cells.  
These results provide evidence for an involvement of PP2A subunit Bα in neuronal 
differentiation. Our results also back the hypothesis that reduced amounts of neuronal Bα-
containing PP2A heterotrimers contributes to MT destabilization and therefore to formation 
of neurofibrillary tangles in Alzheimer´s disease.  
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Abstract in German 
Die Funktion von PTPA in der Biogenese von PP2A in Säugetierzellen 
Proteinphosphatase 2A (PP2A) ist eine essentielle Protein-Serin/Threonin Phosphatase und 
ein Paradebeispiel für die molekulare Architektur von Enzymen, die aus mehreren 
Untereinheiten aufgebaut sind. 
PP2A setzt sich aus folgenden Untereinheiten zusammen: Aus einer katalytischen 
Untereinheit, einer strukturgebenden Untereinheit und einer von vielen regulatorischen 
Untereinheiten, die für Substratspezifität, subzelluläre Lokalisation und katalytische Aktivität 
verantwortlich sind. 
Einer ungebundenen katalytischen Untereinheit fehlt die Substratspezifität, die sie erst durch 
Bindung an eine der vielen regulatorischen Untereinheiten erlangt. Freie und aktive 
katalytische Untereinheiten würden deshalb ein Risiko für Zellen darstellen.  
In einer vorhergehenden Studie im Labor von E. Ogris wurde im Modellorganismus Hefe 
nachgewiesen, dass die katalytische Untereinheit in inaktiver Form und mit veränderter 
Konformation vorliegen kann (Fellner et al., 2003). Die Aktivierung der katalytischen 
Untereinheit durch den Aktivator RRD (Rapamycin Resistant Deletion) ist dabei eng an den 
Aufbau des Holoenzyms gekoppelt. So wird sichergestellt, dass die katalytische Untereinheit 
erst nach Bindung an die regulatorische Untereinheit aktiv wird. Die experimentelle Evidenz 
für dieses Modell wurde bisher nur in Hefe erbracht.  
Erste Komplementierungsexperimente mit dem RRD-Säugetierhomolog PTPA („PP2A 
Phosphatase Aktivator“) in Hefe zeigten die konservierte Funktion von PTPA. RNA-
interference Experimente bewiesen darüber hinaus die essentielle Funktion in Säugetierzellen. 
Dennoch, der direkte Beweis, dass die katalytische Untereinheit auch in Säugetierzellen in 
einer inaktiven Form vorliegt, die durch PTPA aktiviert wird, fehlt. 
Das Thema dieser Arbeit war es daher, die Rolle von PTPA in der Biogenese von PP2A in 
einem Säugetier-Zellkultursystem zu studieren, indem die Expression von PTPA durch 
induzierbare RNAi gezielt supprimiert werden sollte. 
Darüber hinaus wurde in von Alzheimer betroffenen Hirnregionen eine verminderte PP2A 
Aktivität festgestellt. Dies führte zu unserer Arbeitshypothese, dass PTPA als möglicher 
Aktivator von PP2A bei Fehlfunktion eine wichtige Rolle bei der Alzheimer´schen Krankheit 
spielen könnte. Um diesen Zusammenhang in einem Neuronen-ähnlichen System studieren zu 
können, wählten wir Neuroblastoma-Zelllinien als Modellsystem.  
Zusätzlich zu der bereits von Fellner etablierten shRNA, die an den ORF von PTPA bindet, 
wurden zwei neue shRNA Sequenzen, die an die 3´UTR von PTPA binden, als Kontrolle 
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entworfen. Ich konnte zeigen, dass Expression beider shRNA Sequenzen signifikanten 
Knock-down von PTPA bewirkten. 
Zusätzlich wurden ebenfalls als Kontrolle zu allen drei shRNA Sequenzen dazugehörige 
“mismatch” shRNA Sequenzen kloniert. Außerdem wurde eine RNAi-insensitive PTPA c-
DNA hergestellt, durch die Komplementationstests durchgeführt werden können. 
Die ersten PTPA knock-down Klone verloren innerhalb von vier Wochen ihre Fähigkeit die 
Expression von PTPA zu reduzieren. Um dieses Phänomen beim Etablieren der nächsten 
Klone zu verhindern, wurden die verantwortlichen Gründe untersucht: 
Ich konnte zeigen, dass die verwendete Mutterzelllinie N2aTRex eine niedrige Induzierbarkeit 
und eine hohe Expression von Reportergenen in Abwesenheit des Inducers Doxycyclin 
aufweist. 
Nach Etablierung einer Methode zur Detektion und Quantifizierung von Tetracyclin, konnte 
ich nachweisen, dass das von mir zur Herstellung der Klone verwendete FCS 10
-10
g/ml 
Tetracyclin enthielt. 
Sowohl die niedrige Induzierbarkeit und die Kontamination von FCS mit Tetracyclin, als 
auch die Tatsache, dass Suppression der PTPA Expression in HeLa Zellen Apoptose induziert 
könnten zu dem Verlust der Fähigkeit die Expression von PTPA zu supprimieren und 
erschwerter Etablierung von PTPA knock-down Klonen führen. 
Dennoch konnte ich, unter Verwendung von garantiert Tetracyclin-freiem FCS, mehrere 
PTPA knock-down Klone etablieren und auf ihre Proliferationsrate, PP2A Komplexbildung 
und PP2A Aktivität untersuchen. 
In meinen Experimenten konnte ich nach Erniedrigung des PTPA Expressionsniveaus auf 
50% keine Änderung in Zellproliferation, PP2A Heterotrimer Komplexbildung und keine 
verminderte Aktivität von PP2A feststellen.  
Weitere Untersuchungen in anderen Zelllinien und Modellsystemen sind daher nötig, um 
Funktion von PTPA und damit die regulierte Biogenese von PP2A in Säugerzellen  
aufzuklären. 
 
Die Funktion der regulatorischen Bα Untereinheit von PP2A in neuronaler 
Differenzierung 
PP2A setzt sich aus einer katalytischen (C), einer strukturgebenden Untereinheit (A) und 
einer von vielen regulatorischen Untereinheiten (B), die für Substratspezifität, subzelluläre 
Lokalisation und katalytische Aktivität verantwortlich sind, zusammen. Die Expression dieser 
verschiedenen regulatorischen Untereinheiten ist dabei einer genauen Kontrolle unterworfen. 
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Die B-Typ Familie setzte sich aus vier verschiedenen Varianten zusammen: Bα, Bβ, Bγ und 
Bδ. Im Gegensatz zu den regulatorischen Bβ und Bγ Untereinheiten von PP2A, die ein raum-
zeitlich hochreguliertes Expressionsmuster aufweisen, wird die Bα Untereinheit sowohl im 
ganzen Körper als auch in der gesamten Entwicklung ubiquitär exprimiert. 
Deshalb wurde lange angenommen, dass PP2A, das sich aus der A, C und Bα-Untereinheit 
zusammensetzt (Bα-PP2A) vor allen Dingen „Housekeeping“-Funktionen ausübt. 
Interessanterweise wurde gezeigt, dass eine niedrige Expression von Bα-PP2A in Gehirnen 
mit den typischen pathologischen Kennzeichen der Alzheimerschen Krankheit (AD) 
assoziiert ist (Sontag et al., 1995, 1996, 1999, 2004; Merrick et al., 1997; Hiraga and Tamura 
2000).  
Es wird angenommen, dass PP2A die wichtigste Tau-Phosphatase darstellt, einem 
elementaren Mikrotubuli-stabilisierenden Protein. Da die Dephosphorylierung von Tau einen 
stabilisierenden Effekt auf Mikrotubuli besitzt, spielt PP2A eine wichtige Rolle in der 
Aufrechterhaltung der MT. Umgekehrt führt die Hyperphosphorylierung von Tau zur Bildung 
von Neurofibrillen, einem wichtigen pathologischen Zeichen von AD.  
Zusätzliche Hinweise auf eine Beteiligung von Bα-PP2A in AD kamen von RNAi-
Experimenten, in denen Suppression von Bα in N2a und NIH3T3 Zellen zu einem 
Zusammenbruch von azetylierten und detyrosinierten Mikrotubuli (MT) führte (Nunbhaki-
Craig et al., 2007). 
Um nachzuweisen, dass ubiquitäres Bα-PP2A nicht nur „Housekeeping“ Funktionen ausübt, 
sondern auch in der Differenzierung von Neuronen, die von der Stabilisierung neu gebildeter 
MT abhängig ist, eine wichtige Rolle spielt, wurde die Expression von Bα in N2a Zellen 
durch RNAi gezielt supprimiert und das Differenzierungsverhalten analysiert. 
Tatsächlich konnten wir in N2a Zellen eine signifikant verminderte Differenzierung nach Bα 
Suppression nachweisen. 
Dieses Ergebnis zeigt, dass Bα-PP2A eine kritische Rolle bei der neuronalen Differenzierung 
spielt. Außerdem unterstützt dieses Resultat die Hypothese dass Bα-PP2A über die 
Regulation von MT eine wichtige Funktion in der Entwicklung von AD hat.  
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1. INTRODUCTION 
Protein phosphorylation – which occurs on serines, threonines or tyrosines - is a reversible 
posttranslational modification that is used in cells for the regulation of multiple processes 
(e.g. cell cycle regulation or signal transduction). Phosphorylation can alter many different 
protein-specific properties, like catalytic activity, subcellular localization or binding activity 
of key regulatory proteins. The process of phosphorylation, which is catalyzed by protein 
kinases, is counteracted by protein-phosphatases, which bring about dephosphorylation. 
Protein kinases have been studied extensively in the past. However in the last few years, it 
became clear that phosphatases play an equally important role in the regulation of all cellular 
processes (for reviews see Virshup, 2000; Millward et al., 1999 and Janssens and Goris, 
2001). 
Studies in yeast revealed the large number of 124 genes coding for protein serine/threonine 
kinases (PSTKs). PSTKs are built up by one amino acid chain, with a conserved catalytic and 
a regulatory domain. They largely obtain substrate specificity by changes in the regulatory 
domain. 
Contrary to this, only 37 genes coding for protein serine/threonine phosphatases (PSTPs) have 
been found in yeast. PSTPs are typically multisubunit enzymes, in which the catalytic and 
regulatory subunits are encoded by different genes. A wide range of different substrate 
specificities in this case is achieved by the combinatorial assembly of a small number of 
catalytic subunits with a larger pool of regulatory subunits to form a big collection of hetero-
multimeric holoenzymes. 
 
According to their specificity, protein phosphatases are grouped into protein-serine/threonine 
phosphatases (PSTPases), protein-tyrosine phosphatases (PTPases) and dual specificity 
phosphatases (DSPases) (Barford et. al. 1998). The serine/threonine phosphatases are divided 
into the PPP and the PPM family. Protein phosphatase 1 (PP1), protein phosphatase 2A 
(PP2A) and protein phosphatase 2B (PP2B), which differ in their sensitivity for inhibitors, 
requirement for cations and in vitro substrate specificity, belong to the PPP family of 
PSTPases. Protein phosphatase C (PP2C) and mitochondrial pyruvate dehydrogenase are 
members of the PPM family (for a review see Wera and Hemmings, 1995). 
1.1. Structure and subunits of protein phosphatase 2A (PP2A) 
Most PSTP´s are multisubunit enzymes in which the catalytic and the regulatory subunits are 
encoded by different genes. PP2A is a prime example of the PSTP multisubunit architecture.  
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Hence the term PP2A does not describe a single enzyme but rather a large family of distinct 
heterodi- and -trimeric complexes (Fellner et al., 2003).  
The core enzyme is a heterodimer, consisting of a 36 kDa catalytic subunit (PP2AC) and a 65 
kDa regulatory A subunit (PP2AA), which forms the scaffold to connect the catalytic and the 
different regulatory B subunits (PP2AB). Association of one of several regulatory B subunits 
determines substrate specificity and subcellular localization of the PP2A holoenzymes (see 
Fig. A, adapted from Jahnsens and Goris, 2001) (Cegielska et al., 1994; Kamibayashi et al., 
1994; Mayer Jaekel et al., 1994; Turowski et al., 1997). 
Structural analysis of a heterotrimeric AB´C complex revealed a horseshoe-shaped A subunit 
holding the C and B subunit together at the upper surface of the molecule. The regulatory B´ 
subunit binds to the C subunit near the active site, thereby defining substrate specificity. (Cho 
et al., 2007). 
 
Fig. A Structure of PP2A 
 
PP2A is built up by catalytic subunit C, structural subunit A and one member of the B/B´/B´´/B´´´ -type subunit 
families. In mammalia, A and C are encoded by two genes (α and β); the B subunits are encoded by four related 
genes (α, β, γ and δ); the B´ family are encoded by five related genes (α, β, γ, δ and ε); the B´´ and B´´´ subunit 
family contain three genes and two genes, respectively. (Adapted from Janssens and Goris, 2001) 
1.1.1. Mammalian catalytic subunit 
In mammals, there are two C subunit isoforms, α and β, which share 97% identity in their 
primary sequence. Both isoforms are ubiquitously expressed, with the α isoform more 
abundant that the β isoform (Arino et al., 1988; Khew-Goodall and Hemmings, 1988). It has 
been shown, that the structure of PP2AC is highly conserved from yeast to man, and maybe 
represents the most conserved of all known enzymes (MacKintosh et al., 1990; Orgad et al., 
1990; Brewis et al., 1990; Sneddon et al., 1990: Cormier et al., 1991; Arino et al., 1993; Van 
Hoof et al., 1995; Ingels et al., 1995; Kinoshita et al., 1996). Deletion of the gene, encoding 
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PP2A catalytic subunit in mouse (Gotz et al.,1998) and yeast (Kinoshita et. al, 1996) is lethal, 
demonstrating that PP2A is essential. 
Overexpression of PP2AC in mammalian cells has long been unsuccessful, due to an 
autoregulatory feedback cycle, ensuring relatively constant levels of PP2A (Baharians et al., 
1998). 
The overall structure of the catalytic subunit of PP2A resembles the one of PP1, although 
there are local structural differences (Xing et al., 2006). For example, the C terminus is 
unique and has a critical role in regulation of PP2A - its methylation facilitates B subunit 
binding by neutralizing charge repulsion. 
The key structure of the catalytic centre of PP2A is a β-α-β-α fold. In the cleft, formed by the 
ß-sheets, three histidines, two aspartic acids and one asparagine are responsible for 
coordination of the binding of two divalent metal ions (Mn
2+
). They are essential for catalytic 
activity and maintenance of the structural integrity of the enzyme (Cho et al., 2007).  
Interestingly, addition of metal ions (like Mn
2+
 or Co
2+
) (Cai, Chu et al. 1995; Endo, Connor 
et al. 1997) is only necessary for catalytic activity of PP2A when treated with reversible 
inhibitors like ATP, NaF or PPi or after long-term storage (Burchell and Cohen 1978; Hsiao, 
Sandberg et al. 1978; Brautigan, Ballou et al. 1982; Cai, Chu et al. 1995). This is probably 
due to a conformational change of the catalytic centre, which decreases the affinity of a metal 
ion to the active site and causes subsequent loss of the ions (Fellner et al., 2003). 
1.1.2. Mammalian A subunit (PR65) 
The A subunit is the structural subunit that links PP2AC subunit with one of the regulatory 
subunits. As is the case for the catalytic subunit, two distinct PR65 isoforms are present in 
mammalia, α and β, which share 86% sequence identity (Hemmings et al., 1990). Both are 
ubiquitously expressed. Binding of the different B subunits to the A subunit is mutually 
exclusive, as they compete for overlapping binding sites on the A subunit (Ruediger et al., 
1994). 
The protein is built up by 15 tandem repeats of a 39 amino acid sequence termed HEAT 
(huntingtin/elongation/A subunit/TOR). Its horseshoe-shaped architecture is due to stacking 
of the repeats.  
1.1.3. Mammalian regulatory subunits 
The most outstanding attribute about regulatory B subunits in mammalian cells is their 
variety, derived from the evolution of different subunit families. 
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At present, on the basis of sequence homology, four different families of B subunits have 
been identified, termed the B (B55/PR55), B' (B56/PR61), B'' (PR48, PR59, PR72/130) and 
B''' PR93/PR110/striatin/SG2NA) families. These families lack sequence similarity, with the 
exception of two conserved A subunit binding domains (Li and Virshup, 2002). 
Mammalian B subunits are expressed in a cell type/tissue-specific and developmental-
dependent manner, thereby determining the activity and substrate specificity of PP2A in a 
spatial and temporal manner (Zolnierowicz and Hemmings, 1994; Strack et al., 1998). 
 
The B or PR55 family 
The B family is encoded by four different genes (Bα, Bβ, Bγ and Bδ). It was shown that Bα, 
and Bδ are ubiquitously expressed throughout the body, whereas Bβ and Bγ are 
predominantly expressed in the brain. Additionally Bβ and Bγ seem to have different 
functions in brain development, as the expression level of Bβ decreases and that of Bγ 
increases after birth (Strack et al., 1998). 
Furthermore it is interesting, that the different isoforms also have different subcellular 
distributions. In contrast to Bα and Bβ, which are localized mainly in the cytosol, Bγ is highly 
enriched in the cytoskeleton. 
 
The B´ or PR61 family 
The B´ family is encoded by five distinct genes, their products named α, β, γ, δ and ε. This 
variety is further increased by the fact, that there are two isoforms of B´β (Bβ´1 and Bβ´2) and 
at least 3 splice variants of B´γ. 
All B´ family members are built up by a highly conserved central region, which may be the 
interaction site for the A and also likely the C subunit. On the other hand the highly variable 
N- and C-terminal regions probably regulate subcellular targeting and substrate specificity. B´ 
family members α, β and ε are concentrated in the cytosol, while the γ isoforms are found in 
the nucleus and B´δ is localized both in the cytoplasm and in the nucleus. 
The B´family members are also expressed in tissue specific manner: B´α and γ are highly 
enriched in heart and skeletal muscle. In contrast to that, B´β and δ are found mainly in the 
brain and seem to be developmentally regulated as indicated by differentiation experiments 
with N2a cells (McCright and Virshup, 1995; Csortos et al., 1996; Tehrani et al., 1996; 
McCright et al., 1996). 
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The B´´ or PR72 family 
Five different B" isoforms are known in mammals: human PR72 and PR130, mouse PR59, 
human PR48, and the
 
recently identified human G5PR (Hendrix et al., 1993; Kono et al., 
2002) 
Two members, PR72 and PR130, are splice variants from the same gene and differ only in 
their N-terminus. Both variants seem to be important in muscle, as indicated by the exclusive 
localization of PR72 and predominant expression of PR130 in heart and skeletal muscle 
(Hendrix, Mayer Jackel et al., 1993).  
PR48 containing PP2A heterotrimers are localized to the nucleus and are selective for Cdc6, a 
component of the cell-cycle control system. As Cdc6 needs to be dephosphorylated to bind to 
the origin recognition complex and thus to initiate DNA replication, it is believed that PR48-
containing PP2A is required for cell cycle progression (Yan et al., 2000). 
PR59 was identified as an interaction partner of the retinoblastoma-like p107 protein. 
Overexpression of PR59 causes a G1/S arrest and corresponds with an increased proportion of 
hyperphosphorylated and thus active p107 (Voorhoeve et al., 1999). 
To sum up, many of the functions of B´´ indicate that they are predominantly related to the 
regulation of the G1/S transition of cell cycle. 
 
The B´´´ or PR93/PR110 family 
Two other proteins, namely striatin (PR110) and S/G2 nuclear autoantigen (SG2NA or PR93) 
were identified and comprised as the new B subunit family B´´´ (Moreno et al., 2000). Both 
proteins are highly enriched in the brain and seem to have an important role in the modulation 
of calcium-dependent
 
neuronal signaling and possibly remodeling of the cellular cytoskeleton 
(Castets et al., 1996; Moreno et al., 2000).  
To summarize, each B subunit family consists of several highly related isoforms, therefore the 
total number of B subunits is further increased to a total of 18 (Fig. A, Janssens and Goris, 
2001).  
Consequently, more than 72 heterotrimeric holoenzymes, with different substrate specificities 
and subcellular localizations can be assembled.  
This explains how the small pool of protein phosphatases can, by combinatorial assembly of 
holoenzymes with different substrate specificities, specifically counteract the activity of the 
large number of kinases in a cell. 
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1.2. PP2A subunits in yeast 
In contrast to the diversity of PP2A subunits in mammalian cells, there are only few subunits 
in budding yeast Saccharomyces cerevisiae. 
Yeast C subunit is expressed in two isoforms, Pph21 and Pph22. A third gene PPH3 with 
high homology to PPH21 and PPH22 was found. Deletion of one of the two isoforms does 
not cause any major defects, but double deletion of both isoforms causes a severe 
proliferation defect. Additional deletion of PPH3 results in cell death (Ronne H. et. al, 1991) 
In yeast there is only one A subunit, named TPD3 (tRNA processing deficient). Many cells in 
tpd3Δ strain become multi-budded and multi-nucleated, which points towards a defect in 
cytokinesis (van Zyl, Wills et. al, 1989). 
The yeast homologues of the B and B´ subunit are encoded by CDC55 and RTS1 respectively. 
Deletion strains of either of the two subunits are viable but show defects in mitosis and 
exhibit high temperature sensitivity (Healy, Zolnierowicz et. al, 1991; Shu, Yang et. al, 1997; 
Eckert-Boulet, et. al, 2006; Wang et, al, 1997). 
1.3. Regulation of PP2A biogenesis  
PP2A is involved in many cellular processes; therefore a tight control is necessary.  
Mechanisms to regulate PP2A comprise changes of its heterotrimer composition, 
phosphorylating the catalytic subunit (Chen et al., 1992; Guo and Damuni, 1993), 
phosphorylating the B subunits (McCright et al., 1996; Usui et al., 1998) and reversibly 
methylating/demethylating the C-terminus of the catalytic subunit (Favre et al., 1994) by 
methyltransferase LCMT (de Baere et al., 1999; Leulliot et al., 2004) and methylesterase 
PME-1, respectively (Ogris et al., 1999).  
One of the most basic control mechanisms is an autoregulatory translational feedback loop of 
the catalytic subunit, which ensures relatively constant expression levels (Baharians and 
Schönthal, 1998). 
Another important determinant is, that the stochiometric levels of the A, B and C subunits 
seem to be balanced, as was shown by RNAi experiments in vivo suppressing the A subunit, 
which lead to the degradation of the untargeted C and B subunits. This suggests that the PP2A 
subunits are stabilized in the holoenzyme, but are unstable as monomeric subunits (Li et al., 
2002; Silverstein et al., 2002). This is supposed to be one of the control mechanisms, 
preventing free and unregulated C subunits, which would constitute a risk for a cell. 
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Yet, until holoenzyme assembly has taken place, there needs to be an additional surveillance 
system for free C subunit either newly translated or transiently free (if recycling occurs) 
(Fellner et al., 2003). 
1.3.1. Posttranslational modifications 
Modulation of PP2A by covalent modifications like phosphorylation or carboxymethylation 
takes place on its conserved C-terminal part. The advantage of regulating PP2A activity by 
posttranslational modifications is its high flexibility and responsiveness to other stimuli. 
 
Phosphorylation 
The PP2AC can be reversibly phosphorylated on Tyr
307
 located at its carboxy terminus, 
resulting in transient inactivation (Chen et al., 1992; Chen et al., 1994). External stimuli, like 
epidermal growth factors, insulin, interleukin-1 or tumor-necrosis factor α cause increased 
phosphorylation of PP2A C subunit (Guy et al., 1995). So, the transient inactivation of PP2A 
could be one way to speed up cellular communication through kinase cascades. 
The regulatory subunits, particularly the B´ type subunit family, are also phosphorylated. This 
induces changes ranging from altering substrate specificity to increasing the activity of the 
PP2A holoenzyme (Usui et al., 1998; Xu et al., 2000). 
 
Methylation 
PP2A can be methylated on the carboxy group of Leu
309
, located on the C-terminal residue. 
Methylation of PP2A is regulated by the counteractive activities of the PP2A methylesterase-
1 (PME-1) and leucine carboxyl methyltransferase-I (LCMT-I) (Lee et al., 1993; Xie et al., 
1994; Favre et al., 1994; Ogris et al., 1999; DeBaere et al., 1999).  
Methylation of PP2A C subunit has been shown to be necessary for the formation of stable 
PP2A heterotrimers (Wei et al., 2001; Tolstykh et al., 2000; Wu et al., 2000; Yu et al., 2001). 
Deletion of PPM-1 in yeast leads to a PP2AC subunit with decreased affinity to the A subunit 
and completely prevents binding of a B subunit to the AC dimer (Wu et al., 2000; Wei et al., 
2001) and also leads to decreased catalytic activity in yeast (Fellner et al., 2003). In 
mammalian cells, methylation is required for the binding of B/PR55 and B’’/PR72 whereas it 
seems to be dispensable for members of the B’’’/striatin/SG2NA family (De Baere et al., 
1999; Moreno et al., 2000). 
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So, the absence of methylation of free monomeric C subunit, isolated from PPM-1 deletion 
strains, is accompanied by abolished heterotrimer formation and reduced catalytic activity. 
Contradictory to that, free monomeric C subunit, isolated from wild-type cells and 
therefore from pre-existing holoenzymes shows an increased catalytic activity. (Tung et 
al., 1985; Mumby et al., 1985)  
Therefore it seems that activation of PP2AC and holoenzyme formation is dependent on 
PPM1 function. 
1.3.2. PTPA, the PP2A phosphatase activator 
In a study, published in 2003 by Fellner et al., it was shown, that yeast PP2AC requires a 
protein named RRD (rapamycin resistant deletion), to assemble into an active and specific 
PP2A complex. There are two genes in yeast, called RRD1 and RRD2, comprising this 
function. Loss of PTPA function in yeast produces an unstable and metal-dependent form of 
PP2A with a decreased capacity to dephosphorylate serine/threonine phosphorylated 
substrates (Fellner et al., 2003). 
Moreover, loss of the PTPA homologue in yeast leads to a PP2AC with an eightfold increase 
of activity towards tyrosine-phosphorylated substrates, compared to the wild-type protein. As 
phospho-tyrosines (P-Tyr) are more bulky than phosphoserines/–threonines (P-Ser/Thr), it has 
been suggested that PTPA induces a conformational change in PP2A. 
The mammalian homologue PTPA (PP2A phosphatase activator) is able to partially rescue 
the phenotype of an rrd1Δ/rrd2Δ deletion strain. These results were summarized in a model, 
where PTPA/RRD induces a conformational change in the catalytic site of PP2AC. This 
change narrows the catalytic site, so that only the more compact P-Ser/Thr substrates can 
enter. Additionally, this produces a high affinity conformation for metal ions, rendering the 
produced PP2A metal-independent (see Figure B) (Fellner et al., 2003).  
 
Figure B: Model of RRD/PTPA function 
 
Para-nitrophenyl phosphate (pNPP) represents a bulky P-Tyr like substrate; P-Ser/P-Thr: phospho-serine / 
phospho-threonine substrate 
M1 and M2 indicate metal ion 1 and metal ion 2, respectively, located at the catalytic core of PP2AC. The 
indicated amino acid residues represent amino acids of PP2AC that are required for metal ion coordination and 
catalysis. (D) Asp; (H) His; (N) Asn; (R) Arg; (Y) Tyr. (Adapted from Fellner et al., 2003) 
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Recently, PTPA was reported to be a peptidyl prolyl cis/trans-isomerase, targeting Pro
190
 near 
the active site of the C subunit. This enzyme catalyzes the transformation between the cis- and 
trans-conformation of proline and thus can also cause a conformational change in the whole 
protein (Jordens et al., 2005). PPIases minimize the energetic cost of the rotation around the 
C-N bond by binding and stabilizing the transition state (Harrison and Stein, 1990). The 
molecular basis of PTPA function was defined further through crystal structures: 
PTPA is a bilobal molecule, built up entirely by α-helices. Most of the conserved residues are 
found in a groove between the lobes. Within this groove the absolutely conserved Trp
202
 
seems to have an important function, as it directly stacks with the proline
190
 of the PP2AC 
subunit and its mutation causes significant reduction in PTPA´s capacity to activate PP2A and 
reduction in its in-vitro PPIase activity. However, this mutation does not disrupt the in-vitro 
PPIase activity, using another substrate, which could reflect a limitation of this assay for 
mutations or it could be argued, that in addition to the PPIase activity, another function is 
necessary to activate PP2A (Leulliot et al., 2006). 
The activation of PP2A by PTPA provides a surveillance mechanism, keeping free C subunit 
in check, until holoenzyme assembly has occurred. 
1.3.3. Activation and Holoenzyme formation of PP2A in yeast 
Composition of the heterotrimer is mostly determined by availability of the different B 
subunits, thus determining localization and substrate specificity of PP2A. As mentioned 
above, the different B subunits exhibit specific temporal and spatial expression patterns. This 
regulates the assembly of particular PP2A complexes in an on-demand–fashioned manner.  
Deletion of RRD1 and RRD2 in yeast results in a catalytic subunit with a conformation 
different from the wild-type C subunit and a decreased catalytic activity towards P-Ser/Thr.  
Furthermore, knock-out of the gene, coding for A subunit in yeast, tpd3 leads to reduced 
catalytic activity and to abolished holoenzyme assembly. This demonstrates its important 
function as a scaffolding protein but also indicates the importance of holoenzyme assembly 
for activation of PP2A (Hombauer et al., 2007). 
Interestingly, deletion of PPM-1 leads to disruption of holoenzyme assembly and to decreased 
catalytic activity of PP2A (Hombauer et al., 2007). 
In contrast to that, deletion of PPE-1 in Δtpd3 strains, leads, in absence of the holoenzyme, to 
a restoration of catalytic activity. On the other hand, deletion of PPE-1 in rrd1/rrd2 knock-out 
strains leads to the production of inactive PP2A heterotrimers.  
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Moreover, a high level overexpression of PPE-1 in wild-type cells correlated with a 
significant increase in PPE-1:PPH21 complexes and a profound reduction of TPD3 and RRD2 
in complex with PPH21 accompanied with a markedly reduced PPH21 phosphatase activity. 
This suggests that PPE-1 also competes for PPH21-binding with RRD and TPD3. 
Putting these results together, Hombauer et al. proposed a model, where the activation of 
PP2A C subunit is tightly coupled to holoenzyme assembly and where both processes are 
regulated by its methylation status: 
First the scaffolding subunit TPD3 builds a complex with RRD2 and PPH21 subunit, thereby 
repelling PPE-1. Next C subunit can be methylated by PPM1 and RRD2 can exert its 
function. Then, CDC55 or RTS1 binds to the complex, finishing the formation of an active 
heterotrimer. Thus the risk of an active and monomeric, thus unspecific C subunit is avoided 
by producing an inactive precursor, that must not be activated by RRD before holoenzyme 
assembly has occurred. Consequently, binding of free C subunit to PPE-1, keeping it 
demethylated prevents its untimely activation (Hombauer et al., 2007) (see Figure C).  
 
Figure C: RRD/PTPA-dependent generation of active PP2A C subunit is coupled to holoenzyme assembly 
and regulated by methyl-esterase/-transferase enzymes (Hombauer et al., 2007). 
 
However, this model raises the question, what keeps the activated and unspecific AC dimer in 
check, until the regulatory B subunit assembles. A possible explanation could be, that 
phosphorylated B subunits are a substrate for the RRD2:TPD3:PPH21 complex, providing an 
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affinity that is high enough, to minimize the temporal gap to a neglectable period. By 
activating B-type subunit-specific kinases, the cell could therefore regulate the assembly of 
specific complexes. 
1.3.4. Activation and Holoenzyme formation of PP2A in mammalian 
cells 
The activation mechanism for PP2A in mammalian cells is still unknown and is subject to this 
study. 
However, it was shown, that PTPA is able to partially complement the function of RRD1/2 in 
rrd1/rrd2 knock-out in yeast. Moreover, RNA-interference experiments revealed, that PTPA 
is essential for mammalian cell survival in HeLa cells (Fig. D) (Fellner et al., 2003). 
However, direct evidence that PTPA fulfils the same function in mammalian cells, like 
RRD1/2 in yeast is still missing.  
Therefore the major goal of this project was, to study the role of PTPA in the biogenesis of 
PP2A in mammalian cells, by suppressing its expression using RNAi. 
As the suppression of PTPA by RNAi was shown to trigger apoptotic death in HeLa cells, we 
chose to use an inducible RNAi system in order to be able to analyze the PP2A biogenesis 
biochemically upon gradual suppression of PTPA. 
 
Fig. D Suppression of PTPA expression by RNAi triggers apoptotic cell death in mammalian cells.  
 
HeLa cells were co-transfected with the pRETROKatze vector containing the coding sequence of the puromycin 
resistance marker and of the green fluorescence protein (GFP) and either empty pSUPER vector (pSUPER), 
pSUPER-NS-PTPA containing a “nonsense”-targeting sequence (NS-RNAi) or pSUPER-PTPA containing a 
PTPA-targeting sequence (PTPA-RNAi). Cells were stained with antibody specific for active caspase-3 and 
counterstained with DAPI. GFP-staining indicates co-transfected cells. Confocal microscopy images of 
representative cells are shown. (Adapted from Fellner et.al, 2003) 
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1.4. RNA interference 
RNA interference (RNAi) is an evolutionarily conserved mechanism used by the cell that 
permits a sequence-specific post-transcriptional down-regulation of target genes. 
The discovery of RNAi was first noted in plants, where it was termed co-suppression (Napoli, 
1990; Van Blokland, 1994) and later in the nematode Caenorhabditis elegans (Fire et al, 
1998). An RNAi pathway has since been shown to be present in most eukaryotes. 
1.4.1. Mechanism of RNAi 
Briefly, the presence of double-stranded RNA (dsRNA) in cells results in the degradation of 
homologous mRNA und thus to silencing of target genes.  
Described in more detailed, dsRNA is processed into 21-23bp short interfering RNA (siRNA) 
by a ribonuclease called Dicer (Myers et al., 2003). These siRNAs are subsequently 
incorporated into an effector complex called the RNA-induced silencing complex (RISC). 
The 3´ region of siRNA, referred to as the “seed region” first binds to the homologous 
mRNA, guiding the RISC complex to the appropriate target. The complex selectively 
degrades the bound mRNA strand, thereby inducing gene silencing (Fig. E) (Martinez, et al., 
2002; Khvorova, et al., 2003; Schwarz, et al., 2002; for reviews see Hannon, 2002; 
Tijsterman, et al., 2002; Dykxhoorn, et al., 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. E: Schematic diagram of the mechanism of RNA interference. 
 
Dicer binds to dsRNA and digests it into 21 to 23 nucleotide duplexes. These in turn are incorporated into the 
RISC, which has been suggested to eliminate one of the strands and so initiate a cyclical process as the siRNA 
associates with new target molecules (adapted from Kumar et al., 2007). 
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Three types of small RNA can be used to perform RNAi in mammalian cells: chemically 
synthesized siRNA or short hairpin RNA (shRNA) and micro-RNA adapted short-hairpin 
(shRNAmir) both cloned into plasmid DNA vectors.  
The effects of synthetic siRNA are transient, lasting only for 3-5 days in cell culture and are 
therefore not sufficient for studies of proteins with long half-lives (Holen, et al., 2002). 
Another limitation inherent in transient transfection of siRNA is the variability of transfection 
efficiencies. Moreover, siRNA-concentrations, necessary for efficient knock-down are subject 
to concentration-dependent off-target effects (Jackson et al., 2003; Haley and Zamore, 2004; 
Persengiev et al., 2004). 
The solution to all these limitations is the use of plasmids or viral vectors, coding for shRNA: 
First, vector-based RNAi is not transient and allows the co-expression of reporter genes, such 
as GFP or resistance genes, facilitating tracking and/or selection of transfected cells. And 
second, shRNA based systems are less susceptible to concentration-dependent off-target 
effects, as the processing of shRNA by the cellular machinery is a rate-limiting step (Jackson 
et al., 2003).  
Most frequently, RNA-polymerase III promoters (U6, H1 or 7SK) mediated transcription of 
short hairpin structures with a stem of 19-29bp joined by a short loop of 4-10nt are used 
(Brummelkamp et al., 2002; Harborth et al., 2003; Paddison, et al., 2002). 
The hairpin is formed by complementary regions, folding back on themselves, analogous to 
the natural micro-RNA. Recognition and processing of shRNA by the cellular RNAi 
machinery produces siRNA (Brummelkamp, et al., 2002; Miyagishi, et al., 2004). 
1.4.2. Inducible RNAi systems 
A doxycycline inducible form of the RNA polymerase III H1 promoter has been developed by 
replacement of a 19bp sequence between the TATA box and the transcription start site with a 
binding site (tetO) for the tetracycline repressor. 
Binding of the repressor to the tetO site blocks transcription, whereas addition of the inducer 
tetracycline, or its derivative, doxycycline, leads to dissociation of the repressor, allowing 
expression of siRNA and in turn the down regulation of the target gene (Amar, et al., 2006).  
As the tet-responsive polymerase III promoters display some level of leakiness, a vector, 
named pNTO with a more tightly regulated H1 promoter was recently described. This 
expression system contains two optimally placed tet operators and displays low basal 
transcriptional activity and effective silencing in the induced state (Figure G, adapted from 
Strack et al., 2004) (Strack et al., 2004). That system was used for the following study.  
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Fig. G. Schematic of inducible RNAi expressing vector pNTO  
 
In the absence of inducer, tetracycline repressor (TetR) binds to the TO sites of the H1-TO promoter, blocking 
transcription of shRNA. Addition of doxycycline/tetracycline dissociates TetR from the promoter, allowing 
transcription of the shRNA to occur. (Adapted from Strack et. al, 2004) 
 
As the pNTO system requires the function of the native TetR, a stable TetR-expressing cell 
line was generated by Petra Weidinger. N2a were transfected with the vector pcDNA
TM
6/TR 
(Invitrogen) that contained the coding sequence of the native tet-repressor and a blasticidin 
resistance marker. After selection with blasticidin, single clones were isolated and tested for 
expression of tet-repressor and for their ability to block expression. Clone #14 (N2aTRex14) 
was chosen as the parental cell line to be used in the generation of PTPA knock-down cell 
lines. 
1.4.3. Designing efficient siRNAs 
Only 50 percent of siRNAs or shRNAs with exact complementarity to a target mRNA will 
result in effective silencing of the target mRNA (Elbashir, et al., 2002). Recently, various 
design rules have been identified to improve the frequency of designing functional siRNA: 
Standard siRNAs are designed as 19-23bp oligonucleotides with 2nt 3′ overhangs and a 
preference for uridine residues in the 3′ overhang (Elbashir, et al., 2001). A GC content of 
about 50% should be ensured and strings of three or more G or C residues should be as well 
avoided as mRNA areas with complex secondary structures (Far and Sczakiel, 2003; Bohula, 
et al., 2003). 
Moreover, different algorithms have been developed to further facilitating the process of 
designing efficient siRNA sequences (Reynolds, et al., 2004; Ui-Tei, et al., 2004; Boese, et 
al., 2005;Levenkova, et al., 2004; Chalk, et al., 2004; Naito, et al., 2004;  Saetrom and Snove 
Jr., 2004; Yiu, et al., 2005; Santoyo, et al., 2005; Teramoto, et al., 2005).  
Nevertheless, testing of siRNAs in an experiment is still the only effective validation for 
functional siRNAs. 
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1.4.4. Target validation 
A major difficulty in using siRNA is that siRNAs and shRNAs can induce non-specific 
alterations in gene expression (Jackson et al., 2003; Sledz, et al., 2003; Bridge et al., 2003). 
For this reason, all siRNA experiments should be controlled such, that an observed phenotype 
can be confidently linked to silencing of the targeted gene and not be due to an off-target 
effect of the siRNA. 
As a first step, any siRNA being considered should be filtered through a sequence alignment 
algorithm (e.g., BLAST). Only siRNAs with as little identity with other transcripts as possible 
should be selected. A minimum of two mismatches (one centrally placed mismatched 
mutation and a second mismatch either downstream or upstream of the first mismatch) is 
usually sufficient to eliminate RISC-mediated cleavage (Rodriguez-Lebron E. and Paulson H. 
L., 2006) 
As a negative control, so-called “mismatch-RNAi”, where 3 critical positions of the siRNA 
19-mer are changed, should be used. Studies in drosophila have shown that not all positions 
of a siRNA molecule are equally important for target recognition. Of particular importance is 
the centre of the siRNA (Elbashir, 2001). Additionally, it was shown, that specific residues at 
every third position (4, 7, 10, 13, 16, 19) of siRNAs greatly influence its RNAi activity 
(Katoh et al., 2007). Therefore, Positions 4, 10 and 16 were changed in the shRNA molecules 
used, to produce the respective “mismatch-shRNA”. 
Two ways to validate an RNAi induced phenotype are reproduction and complementation. 
The most commonly used control reproduces the phenotype with an additional, independent 
siRNA, targeting unrelated sequences of the target mRNA (Jackson et al., 2003). On the other 
hand, complementation or rescue experiments use the overexpression of siRNA-insensitive 
gene copies of the target gene, to eliminate the siRNA-mediated phenotype. This is mostly 
done by expressing a cDNA encoding the target gene, containing translationally silent 
mutations. When siRNAs are designed to target the untranslated region of an mRNA, wild-
type cDNA can be used to rescue the phenotype (Lassus, et al., 2002). 
Therefore, additionally to the RNAi sequence used by Fellner et al., targeting the C-terminal 
part of PTPA, two additional RNAi sequences were designed, targeting the 3´UTR of PTPA. 
This was done, to be able to reproduce the possible phenotype of PTPA knock-down with 
unrelated sequences and to be able to complement the possible phenotype by the 
overexpression of a wild-type cDNA copy of PTPA. 
Moreover, mismatch RNAi sequences with residues 4, 10 and 16 exchanged were designed, 
cloned and used as a control for every RNAi sequence used in this study. 
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Additionally, in order to be able to complement the possible effects of the knock-down 
induced by RNAi targeting the C-terminal part of PTPA, we designed and cloned an RNAi-
insensitive PTPA version. 
1.5. PP2A in Alzheimer Disease (AD) 
Alzheimer disease is characterized by progressive dementia that will end ultimately in the 
disability of the patient to master the own life and the need for long-time care. Dementia in 
AD is due to massive death of hippocampal and cortical neurons resulting in brain atrophy. 
The major histopathological hallmarks of AD neurons are amyloid plaques and neurofibrillary 
tangles.  
Amyloid plaques are deposits of aggregated ß-amyloid peptide, a 42-amino-acid toxic peptide 
that descends from an abnormally processed ß-amyloid precursor protein.  
Neurofibrillary tangles consist of an abnormally hyperphosphorylated intracellular protein 
named tau, tightly wound into paired helical filaments. Tau is a neuronal-specific microtubule 
(MT)-associated protein, which binds to microtubules and thereby increases their stability (for 
a review, see Tian et al., 2002). 
Phosphorylation of tau leads to dissociation from the microtubule and therefore to reduced 
stability (Illenberger, et al, 1998; Biernat, et al., 1993; Leger, et al, 1997; Xie, et al., 1998). In 
healthy adults tau is phosphorylated on only a few sites. However, in AD affected brains, tau 
is hyperphosphorylated (Morishima-Kawashima, et al., 1995; Matsuo, et al., 1994), which is 
thought to impact microtubule assembly and protein trafficking, resulting in apoptosis 
(Mandelkow et al., 1995). 
The hyperphosphorylation of tau is due in part to decreased tau phosphatase activity (Matsuo, 
et al., 1994). Several indications suggest an involvement of PP2A in this process:  
PP2A was first shown to be capable to dephosphorylate tau, in a biochemical experiment, 
where AD brain derived hyperphosphorylated tau was dephosphorylated by PP2A (Gong et 
al., 1994). 
Experimental indications that PP2A is involved in tau pathology in vivo came from analysis 
of AD affected brain regions, where decreased PP2A catalytic activity (Gong et al., 1993), 
PP2A mRNA expression (Vogelsberg-Ragaglia et al., 2001) and a decreased level of the main 
brain PP2A holoenzyme ABαC (Sontag et al., 2004) were demonstrated. Also PP2A activity 
negatively correlated to the level of tau phosphorylation in human brains (Sontag et al., 2004).  
As PP2A activity is accountable for 71% of total tau phosphatase activity in the human brain 
it was considered to be the major tau phosphatase (Liu et al., 2005).  
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Additionally, it was shown that PP2AC directly binds to tau and microtubules and that 
suppression of PP2A activity in a cell culture system by ocadaic acid (OA) or overexpression 
of SV40 small t, induces AD-like hyperphosphorylated tau, microtubule destabilization, 
modification of synapse structure, and neurodegeneration (Arias et al., 1993; Sontag et al., 
1995; Sontag et al., 1996; Merrick et al., 1996; Merrick et al., 1997; Malchiodi-Albedi et al., 
1997; Sontag et al., 1999). 
Injection of OA into the brain causes tau hyperphosphorylation, neurodegeneration and 
memory impairment in rats (Arendt et al., 1995). Also, the expression of a dominant negative 
PP2A mutant in mice led to pathological tau hyperphosphorylation in vivo (Kins et al., 2001). 
PP2A-dependent PI 3-kinase signaling also plays a crucial role in neuronal survival. It was 
hypothesized by E. Ogris and E. Sontag that disruption of normal brain PP2A functions by 
malfunction of PTPA could lead to the pathogenesis of AD and other neurodegenerative 
diseases. 
Therefore, another goal of this study was the analysis of the tau phosphorylation status in cells 
with reduced PTPA levels. This would answer the question, whether the deregulation of 
PP2A is a cause or a consequence of the tau pathology. 
To be able to study tau-phosphorylation in a cell culture system as similar as possible to the 
cellular situation in the brain, neuroblastoma (N2a) cells, having neuronal characteristics, 
were chosen as the parental cell line for all experiments. 
1.6. The Role of PP2A B-type subunit Bα in differentiation of 
neuronal cells 
Protein serine-/threonine phosphatase 2A (PP2A) is a multifunctional regulator of cellular 
signaling. Variable regulatory subunits associate with a core dimer of scaffolding and 
catalytic subunits and are postulated to dictate substrate specificity and subcellular location of 
the heterotrimeric PP2A holoenzyme.  
In contrast to others, PP2A containing the regulatory subunit Bα, is expressed ubiquitously 
throughout the body, which indicates this enzyme to be a “housekeeping” phosphatase. 
Nevertheless, ABαC was identified as the major phosphatase for tau and therefore an 
important regulator of microtubule dynamics, implicating a possible role in neuronal 
differentiation. 
Moreover, Schild et al. (Schild et al, 2006) showed that Bα protein levels were unaltered, 
while Bβ and Bγ protein levels are reduced after differentiation. On the other hand, 
overexpression of the PP2A regulatory subunit Bγ promotes neuronal differentiation by 
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activating the MAP kinase cascade (Strack et al. 2002), indicating partly redundant roles of 
the different B subunits. 
To clarify the role of PP2A regulatory subunit Bα in neuronal differentiation, differentiation 
of  the N2aTRex14 subline of N2a cells was analyzed upon RNAi-induced reduction of Bα. 
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2. MATERIALS AND METHODS 
2.1. Tissue culture 
2.1.1. Solutions, media and cell lines 
10xPBS: Dissolve in ddH2O: 80g NaCl, 2g KCl, 2g KH2PO4, 14,4g Na2HPO4, adjust to a 
final volume of 1l, adjust to pH 7.4, autoclave and store at RT. 
DMEM: add 50ml FCS and 5mml antibiotic mix to 450ml of DMEM medium under sterile 
conditions (Sigma #D-5523).  
Antibiotic mix: Dissolve 0,6g Penicillin-G and 1g Streptomycin-sulfate in 10ml 10xPBS, 
filter sterilize through a membrane filter (0.2µm) and store aliquots of 5ml at –20°C. 
Trypsin: Dissolve 250mg trypsin in 25ml 10xPBS and add water to a total of 245ml. Stir for 
2 hours. Add 5ml 1% Na-EDTA pH 7.4, mix and filter sterilize through a membrane filter 
(0.2µm). Store aliquots of 10ml at –20°C (Serva#37290). 
Blasticidin: Dissolve 2,5mg/ml in H2O, filter sterilize through a membrane filter (0.2µm), 
use to an end concentration of 5µg/ml (Invitrogen #R210-01)). 
Puromycin: Dissolve 10mg/ml in H2O, filter sterilize through a membrane filter (0.2µm), 
use to an end concentration of 5µg/ml for N2a cells and 0,8µg/ml for HeLa cells 
(concentrations derived from Fellner et al, 2003) (Sigma #P-7255). 
Hygromycin B: Dissolve 50mg/ml in H2O, filter sterilize through a membrane filter (0.2µm), 
use to an end concentration of 200µg/ml for Hek293TRex cells (concentration according to 
recommendation of Invitrogen) (Calbiochem #400049). 
Doxycycline: Dissolve 1mg/ml in H2O, filter sterilize through a membrane filter (0.2µm), use 
to an end concentration of 1µg/ml (Sigma #D-9891). 
Geneticin: Dissolve 10mg/ml in DMEM +Pen/Strep, filter sterilize through a membrane filter 
(0.2µm), use to an end concentration of 600µg/ml for all cell lines (concentration according to 
recommendation of Invitrogen) (Gibco #11811-098). 
All-trans retinoic acid: 1mM in DMSO, store light protected at -20°C, use to an end 
concentration of 1% (Sigma #95152-1G). 
 
Cell lines: 
HeLa:   human cervix carcinoma cell line 
HeLaTRex:  human cervix carcinoma cell line stably expressing the Tet- 
  Repressor (kindly provided by Michael Glotzer) 
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N2a:  human neuroblastoma cell line 
N2aTRex14:  human neuroblastoma cell line, stably expressing the Tet- 
  Repressor (established by Petra Weidinger) 
HEK293TRex: human embryonic kidney cell line, stably expressing the  
  Tet-Repressor (kindly provided by Stefan Strack;  
  Strack et al., 2004) 
Pc12TRex:  rat chromaffin cell line, stably expressing the Tet-Repressor  
  (kindly provided by Stefan Strack; Strack et al., 2004) 
All cells are grown in DMEM+10% fetal calf serum. All media are supplemented with 
penicillin (100units/ml) and streptomycin (100µg/ml). All cells expressing the tet-repressor 
are grown in medium containing blasticidin (5µg/ml). 
2.1.2. Propagation of cell lines 
Cells are cultivated in an incubator at 37°C in an atmosphere with 7,5%CO2. 
It is important to split the cells every two or three days according to their doubling time so 
that the cells never become confluent.  
Splitting of cells in Petri dish with 100mm diameter: 
The medium is removed and cells are washed with 5ml PBS. Then 0,5ml Trypsin/EDTA is 
added. The cells are incubated at RT and detached by gentle knocking against the wall of the 
dish. When the cells are detached, the cells are rinsed down the plate with 10ml medium. 
After determination of the cell number, the cells are diluted as required and plated on new 
dishes. 
2.1.3. Quantification of cell number 
For the determination of cell number 20µl of the cell suspension is counted in a Thoma-
chamber. Alternatively 50µl cell suspension is diluted in 5ml CASYton solution and the cells 
are counted by CASY cell counter. 
2.1.4. Freezing/Thawing of cells 
The cells are trypsinised and pelleted by centrifugation. The pellet is resuspended in 
90%FCS/10%DMSO and incubated on ice for 20 minutes. Afterwards the cells are stored for 
at least one day at –80°C and are then transferred to liquid nitrogen. To thaw cells, the frozen 
tube is incubated in a 37°C water bath, until the cell suspension is liquid. Then it is diluted in 
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5ml medium and centrifuged. Finally, the cell pellet is resuspended in the appropriate volume 
of the according medium. 
2.1.5. Transfection of cells 
Cells are transfected using Invitrogen lipofectamine 2000 (Invitrogen #11668-027), using the 
following protocol for transfection in a 24-well format: 
Cells are seeded at high density (0,5-2x10
5
 cells on a 24-well) on the previous day, so that 
cells will be 90-95% confluent at the time of transfection.  
For each transfection sample, 0,8µg DNA is diluted in 50µl DMEM without FCS/antibiotics 
and 2µl lipofectamine are diluted in 50µl DMEM without FCS/antibiotics. After 5 minutes 
incubation at room temperature, the diluted DNA is combined with diluted lipofectamine, 
mixed gently and incubated for 20 minutes at room temperature. 
The lipofectamine/DNA mix is added to the cell directly and transfection is allowed to 
proceed for 4 hours, after which the medium is exchanged. Testing or antibiotic selection 
starts 24 hours post transfection.  
To transfect in different tissue culture formats, use the volumes and amounts as shown below 
(Lipofectamine 2000, manual; Invitrogen): 
Culture vessel Volume of dilution medium 
(DMEM) 
DNA Lipofectamine 2000 
24-well 2x 50µl 0,8µg 2µl 
12-well 2x 100µl 1,6µg 4µl 
6-well 2x 250µl 4µg 10µl 
60-mm 2x 500µl 8µg 20µl 
10-cm 2x 1,5ml 24µg 60µl 
2.1.7. Differentiation of N2aTRex14 cells  
Poly-L-lysine coating of plates and coverslips 
Add 0,001% Poly-L-lysine solution (Stock: 0,01%; Sigma #P8920) to sterilized cover slips in 
multiwell or to a dish: 
Culture vessel Volume of Poly-L-lysine 
24-well 300µl/well 
6-well 500µl/well 
60-mm 1ml 
10-cm 2,5ml 
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Incubate dish with poly-L-lysine for 1 hour, remove and let dish dry for another hour under 
UV-light. Wash dish 4 times with ddH2O and let again dry over night under UV-light. 
 
Differentiation of Bα-knockdown cells  
Cells are seeded on poly-L-lysine coated glass coverslips. After 24 hours, differentiation of 
N2aTRex14 cells is induced by starvation in medium supplemented with 1%FCS or with 
1%FCS and 1% retinoic acid (RA).  
Lightfield microscope pictures of cells are taken 24 and 48hours after starting differentiation 
(complete experimental outline: see Fig. H). 
For estimates of differentiation state of, 4 random visual fields (on average 35 cells/picture) 
(20x objective) for each condition were viewed. The total number of cells visualized under 
phase contrast microscopy and the number of cells with neurites longer than the cell axis 
(differentiated) (see Fig. H) were counted in each visual field. 
Fig. H: Experimental Outline 
Knockdown of PP2A-Bα was induced on day1 by administration of 1µg/ml Dox. After 72 hours cells were 
seeded on Poly-L-Lysine-coated wells and induced to differentiate 24h later with low serum (1% FCS) or low 
serum plus 10µM RA. Doxycycline was added every day for 6 days to maintain knockdown. 
Differentiation was scored on day 6 and 7 by taking photos and counting a minimum of 100 cells/experimental 
condition. Cells with neurite outgrowth longer than the cell body were considered differentiated (see Photo). 
Lysates were prepared on day 4 and 7 (*) to prove that the differentiation starts with reduced levels of PP2A-Bα 
and that Bα-knockdown is stable over the experimental period. 
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2.2. Working with Bacteria 
2.2.1. Solutions, media and bacterial strains 
Luria Bertani (LB) media: 10g Bacto tryptone, 5g yeast extract, 5g NaCl in 1l H2O, 
autoclave and store at room temperature. 
LB-plates: 10g Bacto tryptone, 5g yeast extract, 5g NaCl, 15g Bacto agar in 1l H2O, 
autoclave, cool to 50ºC, add antibiotics and pour plates. Store the plates at 4ºC.  
Ampicillin-stock (100X): prepare a solution of 10 mg/ml in H2O, dissolve, filter sterilize 
through a membrane filter (0.2µm) and store aliquots of 5 ml at -20ºC. (Gerbu #1046) 
Kanamycin-stock (200x): Prepare 10mg/ml in H2O, filter sterilize through a membrane filter 
(0.2µm) and store aliquots of 5ml at –20°C. (Sigma K-4000) 
Tetracycline-stock (100x): Prepare 5mg/ml in 96% ethanol and store aliquots of 5ml at         
–20°C. (Sigma #T-3383) 
Bacterial strains: 
- XL-1 Blue: endA1, gyrA96, hsdR17(rK-mK+), lac, recA1, relA1, supE44, thi-1, F´[ proAB, 
lacI
qZΔM15, Tn10 (Tetr)] (www.neb.com) 
-HB-101: ara14, galK2, hsdS20(rB- mB–), lacY1, Δ(mcrC- mrr), mtl-1, recA13, proA2, 
rpsL20, supE44, xyl-5, F– (www.neb.com) 
2.2.2. Growth of bacteria 
Bacteria are grown in liquid culture or on agar plates containing the appropriate selection 
antibiotics (Amp [100µg/ml]; Kan [50µg/ml]; Tet [25µg/ml] for plates and Amp [100µg/ml]; 
Kan [30µg/ml]; Tet [15µg/ml] for liquid culture) at 37°C. 
2.2.3. Freezing of bacteria 
To store transformed bacteria, 100µl glycerol and 900µl liquid culture are mixed and frozen at 
–80°C. 
2.2.4. Transformation of heat shock competent bacteria  
Thaw an aliquot of competent E. coli and incubate them immediately with 1-100ng plasmid 
DNA on ice for 30 minutes. Heat-shock the bacterial suspension on 42ºC for 90 seconds, then 
incubate the bacterial suspension 5 minute on ice. Add 1 ml LB media without antibiotics and 
incubate the bacteria suspension for 1 hour at 37ºC under shaking. Spread bacterial 
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suspension onto a LB plate containing the right selection antibiotic and incubate overnight at 
37ºC. 
2.3. Working with DNA 
2.3.1. Buffer and Solutions  
EDTA 0.5 M, pH 8.0: Dissolve 186.1g disodium ethylendiamine-tetra-acetate∙2H2O in 
800ml ddH2O and adjust pH to 8.0 with NaOH (titrate with a diluted NaOH solution after 
addition of 18-19 NaOH pellets). Autoclave and store at 4ºC. 
50X TAE: Dissolve in ddH2O: 484g Tris, 114ml acetic acid, 200ml 0.5M EDTA pH 8.0, 
adjust to a final volume of 2l, store at RT. 
PCI (Phenol:Chloroform:Isoamylalcohol) (25:24:1): Mix equal parts of equilibrated phenol 
and chloroform:isoamyl alcohol (24:1) and store under 0,1M Tris pH 8.0 at 4°C in the dark. 
Miniprep solutions: 
Solution I: Dissolve 0,9g Glucose in ddH2O, mix with 2,5ml 1M Tris-Cl  
 (pH 8.0) and 2ml 0,5M EDTA (pH 8.0), fill up to 100ml with ddH2O. 
Autoclave and store at 4°C. 
Solution II: Mix 20ml 1M NaOH with 5ml 20%SDS, fill up to 100ml with  
 ddH2O. Autoclave and store at 4°C. 
Solution III: Mix 60ml 5M Potassium acetate with 11,5ml Glacial acetic acid  
 and fill up to 100ml with ddH2O. Store at 4°C. 
2.3.2. Primers 
sh-DNA 
All shDNAs were designed to the following scheme: 
      Targeting sequence          Complementary sequence 
 
5´-GATCCCC-   5´→3´ 19mer   -TTCAAGAGA-   3´→5´ 19mer     -TTTTTCGAAA-3´ 
3´-         GGG -   3´→5´ 19mer    -AAGTTCTCT-    5´→3´ 19mer- AAAAAGCTTTTCGA-5´ 
 
BamHI adapter sequence            loop       HindIII adapter sequence 
 
 
 
35 
shPTPA-1 
Position of targeted sequence in ORF: 903-921 
Sequence derived from and already confirmed in Fellner et al., 2003 
shPTPA-1forward 
(PTPA-CtfwPetra/#630): 
5´-GATCCCC-GTTCCCTGTGATCCAGCAC- 
TTCAAGAGA-GTGCTGGATCACAGGGAAC-TTTTTGGAAA-3´ 
shPTPA-1reverse 
(PTPA-CTrevPetra/#631): 
5´AGCTTTTCCAAAAA-GTTCCCTGTGATCCAGCAC- 
TCTCTTGAA-GTGCTGGATCACAGGGAAC-GGG-3` 
shControl-1forward  
(PTPA-Ctmisfw/#632): 
5´-GATCCCC-GTTTCCTGTAATCCAACAC- 
TTCAAGAGA-GTGTTGGATTACAGGAAAC-TTTTTGGAAA-3´ 
shControl-1reverse  
(PTPA-Ctmisrev/#633): 
5´AGCTTTTCCAAAAA-GTTTCCTGTAATCCAACAC- 
TCTCTTGAA-GTGTTGGATTACAGGAAAC -GGG-3` 
shPTPA-2 
Position of targeted sequence from start codon ATG in ORF: 1254-1272 
Entry in database, from which name was derived: AY035997 
shPTPA-2forward 
(mmPTPA1360fw/#644): 
5´-GATCCCC-GGACACCCTGCTCTTGTCA- 
TTCAAGAGA-TGACAAGAGCAGGGTGTCC- TTTTTGGAAA-3´ 
shPTPA-2reverse 
(mmPTPA1360rev/#645): 
5´AGCTTTTCCAAAAA-GGACACCCTGCTCTTGTCA- 
                 TCTCTTGAA-TGACAAGAGCAGGGTGTCC-GGG-3` 
shControl-2forward 
(mmPTPA1360misfw/#646): 
5´-GATCCCC- GGAGACCCTACTCTTATCA– 
TTCAAGAGA-TGATAAGAGTAGGGTCTCC- TTTTTGGAAA-3´ 
shControl-2reverse 
(mmPTPA1360misrev/#647): 
5´AGCTTTTCCAAAAA-GGAGACCCTACTCTTATCA-             
                  TCTCTTGAA-TGATAAGAGTAGGGTCTCC-GGG-3´ 
shPTPA-3 
Position of targeted sequence from start codon ATG in ORF: 1692-1710 
Entry in database, from which name was derived: AY035997 
shPTPA-3forward 
(mmPTPA1798fw/#648) 
5´-GATCCCC-GAGACTCCGGGAGGCAGTA- 
TCAAGAGA-TACTGCCTCCCGGAGTCTC- TTTTTGGAAA-3´ 
shPTPA-3reverse 
(mmPTPA1798rev/#649): 
5´AGCTTTTCCAAAAA-GAGACTCCGGGAGGCAGTA-              
                 TCTCTTGAA-TACTGCCTCCCGGAGTCTC-GGG-3` 
shControl-3forward 
(mmPTPA1798misfw/#650): 
5´-GATCCCC-GAGTCTCCGAGAGGCGGTA- 
TTCAAGAGA-TACCGCCTCTCGGAGACTC - TTTTTGGAAA-3´ 
shControl-3reverse 
(mmPTPA1798misrev/#651): 
5´AGCTTTTCCAAAAA-GAGTCTCCGAGAGGCGGTA- 
                TCTCTTGAA- TACCGCCTCTCGGAGACTC-GGG-3` 
 
36 
sh-Bα mismatch: 
Position of targeted sequence from start codon ATG in ORF: 1199-1217 
sh-BαControlforward  
(PP2A-Balphamis_for/#664): 
5´-GATCCCC-GTGACAAGCTAAAGATAGA- 
TTCAAGAGA-TCTATCTTTAGCTTGTCAC-TTTTGGAAA-3´ 
sh-BαControlreverse  
(PP2A-Balphamis_rev/#665): 
5´AGCTTTTCCAAAAA-GTGACAAGCTAAAGATAGA-       
                  TCTCTTGAA-TCTATCTTTAGCTTGTCAC-GGG-3` 
Nucleotides changed in mismatch-oligonucleotides are underlined. 
New PTPA targeting sequences PTPA2 and 3 were designed using the following algorithms: 
- Ambion 
- Jack 
- OptiRNAi 
- Emboss 
- MPI 
- GenScriptDharmaconQiagen 
- SiDirect 
Sense and antisense fragments were hybridized and cloned into the BamHI-HindII sites of a 
linearized H1TO promoter-driven RNAi-ready pNTO vector (Strack). Vector inserts were 
verified by sequencing. Sequence sh-PTPA1, targeting the C-terminal region of PTPA was 
already confirmed to induce knock-down of PTPA transiently in HeLa cells by Fellner et al. 
(Fellner et al., 2003). Sequences sh-PTPA2 and 3 target the 3´untranslated region (3´UTR) of 
PTPA. 
 
Sequencing 
H1 forward (#385): 5´-GAA TCG CGG GCC CAG TGT CA-3` 
T7 forward:  5´-GTA ATA CGA CTC ACT ATA GGG C-3` 
Sp6 reverse:   5´-GAT TTA GGT GAC ACT ATA G -3` 
 
Site-directed mutagenesis 
PTPAmutPCR_BstXIfw (#783): 5´-CTTGATCAGGAAGCAGAA-3´ 
Sp6 reverse:    5´-GAT TTA GGT GAC ACT ATA G -3` 
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mmPTPAmut1fw (#759):   
Nucleotides changed from         C             G             G  
5´-GAGTGCCTGGAGAAGTTTCCTGTAATCCAACACTTCAAGTTCGGGAGC -3´ 
 
mmPTPAmut1rev (#760):   
5´-GCTCCCGAACTTGAAGTGTTGGATTACAGGAAACTTCTCCAGGCACTC -3´ 
Nucleotides changed from wild-type PTPA are underlined. 
2.3.2. PCR (Polymerase Chain Reaction) 
PCRs were performed using: 1xTaq Polymerase buffer w/o MgCl2 containing (NH4)2SO4 
(Fermentas), 0.25mM dNTPs (of each), 5pmol/µl primer (forward and reverse), 2mM MgCl2, 
5 units Taq polymerase (Fermentas) and 0.5-1µg DNA as template.  
The PCR program: 95ºC 2min, followed by 32-35 cycles of subsequent steps of denaturing at 
95ºC 30 sec, annealing at X(*)ºC for 1min and extension at 72ºC for 2 min. The cycling is 
followed by one single extension step at 72ºC for 10 minutes, pause at 4ºC.   
 
Site-directed mutagenesis by PCR 
As a template for site-directed mutagenesis the vector pcDNA3, coding for the expression of 
mammalian PTPA (pcDNA3_mPTPA#1; mouse PTPA) is used.  
To mutate PTPA on position 906, 912 and 918, three PCR reaction steps are performed. The 
first reaction (PCR1) is carried out using a forward primer upstream of the site to be mutated 
(BstXIfw) and a reverse primer, targeting the site to be mutated, with three exchanged bases 
(mmPTPAmut1rev). Correspondingly the equivalent PCR (PCR2) is done with a reverse 
primer downstream of the site to be mutated (Sp6) and a forward primer, again targeting the 
site to be mutated, with three exchanged bases (mmPTPAmut1fw). Primers targeting the site 
to be mutated are designed to produce a shPTPA1-insensitive form of PTPA, but to produce 
silent mutations. Products of PCR reaction 1 and 2 are purified, using Promega PCR Clean-up 
system.  
The third reaction is performed using 25ng of each PCR product and primers 
PTPAmutPCR_BstXIfw and Sp6.  
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After the third PCR, vector pcDNA3_mPTPA#1and PCR product are digested with BstXI and 
XhoI and ligated. For a full graphic representation see Figure I. The generated vector is 
sequenced using primer Sp6 (see attachment for map). 
Fig. I: Scheme of site-directed PTPA mutagenesis using the vector pcDNA3_mPTPA#1 
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2.3.3. Sequencing  
For sequencing 0,5µg template DNA was mixed with 2µl Big dye Terminator Mix, 4µl 
(1pmol/µl) primer, 4µl 5x sequencing buffer and filled up to total volume of 20µl with 
ddH2O. For sequencing sh-RNA expressing vectors, 0,5µg template DNA was mixed with 2µl 
Big dye Terminator Mix, 0,4µl (10pmol/µl) primer, 4µl 5x sequencing buffer, 1µl DMSO, 
12,5µl 2M betain and filled up to total volume of 20µl with ddH2O. 
The sequencing program: 95ºC 2min, followed by 30 cycles: 95ºC 30 sec, 50ºC 30 sec, 60ºC 
1-2 min, 60ºC for 4 minutes, pause at 4ºC.   
After this amplification using the Big dye system, the sequencing reaction is sent to VBC-
genomics where sequencing is performed. 
2.3.4. Methods of cloning and manipulation of DNA 
Restriction digests 
For digesting 1 µg plasmid DNA use 1-5 U of the requested restriction enzyme and prepare 
the reaction mix as suggested by supplier. The final volume of the reaction is usually 100 µl 
for preparative purposes or 30 µl for control digests. Incubate for 1-2 hours at the 
recommended temperature. Usually 1 unit of enzyme digests 1 µg of plasmid DNA in 1 hour 
when incubated at the temperature optimum. For digestion of miniprep DNA, Rnase is used at 
an end concentration of 0,5mg/ml. Stop the reaction by adding 1/10 volume of loading dye.  
Analyze the restriction digests on an agarose gel (0.8-3% in TAE buffer) depending on the 
expected fragment sizes. 
 
DNA precipitation 
Add 1/10 volume of Na-acetate pH 5.2 to the DNA-solution and mix. Then add 2 volumes of 
cold 95% ethanol, mix and keep the mixture for at least 20 minutes at -20ºC. Centrifuge at 
14.000 rpm at 4ºC for 10 minutes. Discard the ethanol and dry the DNA pellet on air. 
Resuspend the DNA in a suitable amount of buffer or ddH2O. 
 
Elution of DNA fragments using QIAquick gel extraction kit 
Use the protocol described by manufactures QIAGEN, QIAquick gel extraction kit #28706. 
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Ligation of DNA fragments with T4 DNA ligase 
Mix plasmid DNA and insert at ratio 1:3-1:5 in a final volume of 20 µl containing 1 µl (400 
U) T4 DNA ligase and 1X T4 ligase buffer. Incubate at 16ºC overnight. Use half of the 
mixture for transformation of competent E. coli. 
 
Annealing of Oligonucleotides 
The ordered oligonucleotides are diluted to 100µM with ddH2O according to the datasheet. 
Then 2µl (200pmol) of the corresponding forward and reverse oligonucleotides are mixed 
with 8µl 5x annealing buffer and filled up with ddH2O to a total volume of 40µl (end 
concentration of [5*10
-3
fM]. The oligonucleotides are annealed by boiling the mixture in a 
water bath at 96°C for 5min and then cooled down to room temperature under constant 
stirring. 
2.3.5. Plasmid Isolation from bacteria 
DNA plasmid isolation using alkaline lysis  
For small scale DNA plasmid preparation the self made MINI preparation solutions and 
following protocol were used.  
6ml overnight culture of bacteria is centrifuged 5min with 5000rpm. The pellet is resuspended 
in 100µl buffer 1 and transferred to an eppendorf tube. 200µl of buffer 2 is added, the tube is 
inverted and incubated for a maximum of 5 minutes at room temperature. After adding 150µl 
buffer 3 and vortexing, the solution is centrifuged at 14000rpm for 10 minutes. The 
supernatant is mixed with 300µl isopropanol by vortexing. After centrifugation at 14000rpm 
for 15 minutes the pellet is washed with 70% ethanol. After centrifugation for 3 minutes at 
14000rpm, the pellet is dried resuspended in 50µl ddH2O. 
 
DNA plasmid isolation using the MIDI preparation kit QIAGEN 
For large scale DNA plasmid preparation the MIDI preparation kit (QIAGEN #12145) was 
used. Follow the instructions as described in the manual. 
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2.4. Working with proteins 
2.4.1. Solutions 
30% Acrylamide: Dissolve 292g acrylamide and 8g bisacrylamide in 1l ddH2O. Add ion-
exchange resin (BioRad AG 501-X6) to the final solution and store at 4ºC in the dark. 
1M Tris pH 8.8: Dissolve 242.3g Tris in ddH2O, adjust to pH 8.8 with HCl and fill up to 2l 
with ddH2O. Autoclave and store at 4ºC. 
1M Tris pH 6.8: Dissolve 60.5g Tris in ddH2O, adjust to pH 6.8 with HCl and fill up to 
500ml with ddH2O. Autoclave and store at 4ºC. 
20% SDS: Dissolve 40g SDS in ddH2O. Stir and heat slightly, if necessary. Add ddH2O to a 
final volume of 200ml and store at RT. 
10% APS: Dissolve 1g ammonium persulfate in 10ml ddH2O and store at 4ºC.  
10X running buffer: 250mM Tris, 2M glycine, 35mM SDS in ddH2O. 
Transfer buffer: 25mM Tris, 190mM glycine, 20% methanol in ddH2O. 
GSD 3X stock (protein sample buffer): 4.5M glycerol, 10ml 20% SDS, 0.33M dithiotreitol 
(DTT) and 10ml ddH2O. Add a bit of bromophenol blue and neutralize with a few drops of 
1M Tris pH 6.8 (the solution should appear blue). Dilute 1:3 in ddH2O before use or dilute 
with the sample. 
3% NFDM blocking solution: Dissolve 30g non fat dry milk (NFDM) in 1l PBS containing 
0.05% Tween 20 (PBS-T), add 50µl 20% sodium azide, mix and store at 4ºC. 
0.5% NFDM antibody incubation solution: Dissolve 5g non fat dry milk (NFDM) in 1l 
PBS-T, add 1ml 1% thimerosal, mix and store at 4ºC. 
IP-wash buffer: 20mM Tris-HCl pH 8.0, 135mM NaCl, 10% glycerol in ddH2O. Filter-
sterilize and store at 4°C. 
IP-lysis buffer: 20mM Tris-HCl pH 8.0, 135mM NaCl, 10% glycerol and 1% (w/v) NP-40 in 
ddH2O. Filter-sterilize and store at 4°C. 
PMSF stock (100X): Dissolve 0.697g of phenylmethylsulfonylfluoride (PMSF) in 20 ml 
isopropanol (2-propanol), make aliquots and store at RT in dark (Roche #10837091001). 
Aprotinin-stock (100X): 10ml Aprotinin (10 TIU (trypsin inhibitor units)/ml; Sigma), 
aliquot and store at 4ºC (Sigma A-6279).  
Complete
TM
 stock (25X): Dissolve one Complete
TM
 Protease inhibitor cocktail tablet (Roche 
#11836145001) in 2ml IP-buffer and store at 4ºC. Prepare fresh every two weeks. 
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Basic buffer used for ß-Gal assay: 25mM tricine, 0,5mM EDTA, 0,54mM Na-
Tripolyphosphate, 16,3 mM MgSO4*7H2O, 0,1% triton X-100 in ddH2O, adjust to pH 7.8 
with NaOH. Autoclave and store at 4ºC. 
0,1M Na-Phosphate buffer pH 7.5: Dissolve 1,78g Na2HPO4*2H2O in 50ml ddH2O (0,2M) 
and 0,31 g  NaH2PO4*H2O in 10ml ddH2O (0,2M). Mix 41ml of 0,2M Na2HPO4*2H2O and 
9ml of 0,2M NaH2PO4*H2O. Adjust to pH 7.5. Add 50ml ddH2O. Autoclave and store at 4°C. 
100x Mg
2+
 solution: 0,1M MgCl2, 4.5M ß-mercaptoethanol in ddH2O. Store at 4°C. 
1xOPNG (o-nitrophenyl-ß-D-galactopyranoside) solution: Dissolve 4mg/ml o-
nitrophenyl-β-D-galactopyranoside in 0,1M Na-phosphate buffer pH 7.5. Prepare fresh, store 
at 4°C (Sigma N1127-25G). 
ß-galactosidase assay buffer: Mix 3µl 100xMg solution, 66µl 1xOPNG solution and 201µl 
0,1M Na-phosphate buffer pH 7.5 per sample [OPNG: 3,24mM]. 
1M Na2CO3 solution: Dissolve 52g Na2CO3 in 500ml ddH2O. Autoclave and store at 4°C. 
2.4.2. Preparation of protein lysates of mammalian cells 
Cells are washed with 5ml PBS and 5ml IP-wash. Add IP-lyse, containing the following 
protease inhibitors:  For 1ml IP-lyse add 10µl PMSF- (final concentration: 2mM), 5µl 
aprotinin-stock (final concentration: 0.05TIU/ml) and 40µl complete-stock. The dish is 
incubated on the shaker for 10minutes at 4°C. The cells are scraped off with a rubber scraper 
and the cell debris is transferred to a 1,5ml tube and again incubated on the shaker for 
10minutes at 4°C. After 10 minutes centrifugation with maximum speed at 4°C, the 
supernatant is transferred to a new tube and proteins concentration can be determined. 
2.4.3. Determination of protein concentration (Bradford) 
Mix 1µl of cell lysate with 1ml of Bradford reagent solution (dilution 1:4 in ddH2O; Bio-Rad 
Protein Assay Dye Reagent #500-0006). Mix and incubate for 10 minutes at RT. Measure the 
optical density at 595nm. For each lysate at least three samples are measured. 
2.4.4. SDS-PAGE (SDS-Polyacrylamide gel electrophoresis) 
Clean the glass plates with ddH2O and ethanol and assemble the gel unit. Mix the components 
for a separating gel except APS and TEMED. Degas the mixture (5 minutes vacuum) and add 
APS and TEMED. Mix and carefully apply the mixture between the glass plates, leaving 2.5 
cm space for the stacking gel. Overlay the separating gel with 1ml ddH2O to ensure an even 
surface. After polymerization of the separating gel, remove the water and fill in the stacking 
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gel. Insert the comb and avoid air bubbles. After polymerization carefully remove the comb 
and wash the slots with ddH2O in order to remove unpolymerized acrylamide. Insert the gel 
unit into the running unit and fill the chambers with 1x running buffer. 
Samples are prepared by mixing the volume of whole cell lysate equivalent to 60µg protein 
with 3xGSD. Each sample is filled up to the same volume with IP lyse solution. 
Load the samples and run the gel overnight at 6-9 mA per gel and stop when the front is 15cm 
past the stacking gel.  
 
 
 
 
 
 
 
 
 
2.4.5. Western blot analysis 
Western transfer 
Carefully remove the glass plates and take out the gel. Cut off the gel below the stacking gel 
and 15 cm from there. Assemble the western sandwich in the following order: 
Support pad, 2 sheets of 3mm Whatman chromatography paper, gel, nitrocellulose membrane 
(Schleicher&Schuell 13.5x15 cm), again 2 sheets of 3mm paper and the other support pad (all 
components soaked with transfer buffer). Avoid air bubbles during the assembly. 
Insert the western sandwich into the transfer unit with the membrane at the plus pole. Transfer 
the proteins at a constant current of 500mA at 4°C for 3.5 hours. 
 
Antibody incubation 
Wash the membrane after the transfer shortly with PBS-T (PBS containing 0.05% Tween 20) 
and incubate with 3% milk (blocking solution) for approximately 1 hour, rocking, at RT. 
After blocking, wash the blot once with PBS-T and incubate it either overnight at 4°C or for 1 
hour at room temperature with the appropriate primary antibody, diluted as listed below, in 
0.5% milk. After incubation, remove the primary antibody and wash the blot three times for 5 
Separation gel: 15% 10% 7.5% 
Acrylamide/Bis (30%) 20ml 13.4ml 10.1ml 
1M Tris pH 8.8 15ml 15ml 15ml 
ddH2O 5ml 11.7ml 15ml 
20% SDS 200µl 200µl 200µl 
10% APS 134µl 134µl 134µl 
TEMED 26µl 26µl 26µl 
Stacking gel:  
Acrylamide/Bis (30%) 1.7ml 
1M Tris pH 6.8 1.25ml 
ddH2O 7.1ml 
20% SDS 50µl 
10% APS 50µl 
TEMED 10µl 
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min with PBS-T. Incubate the blot then with secondary antibody, diluted as indicated below 
in 0.5% milk for 1 hour at room temperature under low shaking. 
 
Immunodetection by enhanced chemoluminescence (ECL): 
After incubation with one of the secondary antibodies coupled to horse radish peroxidase, 
wash the blot three times for 10 minutes with PBS-T and dry the blot between two 3MM 
Whatman-sheets. Mix equal amounts of the two ECL solutions (oxidizing reagent and 
enhanced luminol reagent) and incubate the blot for 1 minute with this mixture. Take out the 
membrane, wrap it in saran wrap and expose the blot to X-ray films.   
Wash the membrane once in PBS-T and incubate for 30min with blocking solution at RT. 
Wash again with PBS-T and incubate with a new primary antibody or dry the blot between 
two 3mm Whatman sheets. 
antibody Directed against dilution Type of antibody kDa 
2G9 Bα, δ-subunit (human) 1:5000 mouse, monoclonal 50 
ß-Actin ß-Actin (human) 1:10.000 mouse, monoclonal 
(Sigma; A1978) 
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PTPA PTPA (mouse) 1:10.000 rabbit, polyclonal 40,6 
SAT20 C-subunit 1:10.000 rabbit, polyclonal, purified 36 
4C10 A-subunit 1:100 mouse, monoclonal 65 
B´-subunit (p56)  B´-subunit 1:1000 rabbit, polyclonal, purified 56 
B´´-subunit (p59) B´´-subunit 1:1000 rabbit, polyclonal, purified 59 
10E2 HDAC1 1:100 mouse, monoclonal 62 
PME-1 PME-1 1:10.000 rabbit, polyclonal 44 
Hsp70 Hsp70 1:2000 mouse, monoclonal 
Upstate, P34932 
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16B12 HA-tag 1:10.000 mouse (monoclonal) 
(Abcam, ab2477) 
 
Secondary antibody  dilution Type of antibody  
HRP anti-mouse IgG, Fcγ fragment-
specific 
1:5000  Goat; Jackson #115-035-
008 
 
HRP anti-rabbit IgG, Fcγ fragment-
specific 
1:5000  Goat; Jackson #111-035-
008 
 
ALEXA anti-mouse  1:20 000 Goat; Invitrogen A-21057  
ALEXA anti-rabbit  1:20 000 Goat; Invitrogen A-21076  
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To quantify expression levels of proteins, the X-ray films are scanned with the Canon 
CanoScan 4200F. The bands are then quantified by using Image Quant 5.0 software. 
 
Immunodetection using the LiCor infrared imaging system 
After incubation with the secondary antibody (ALEXA), wash the blot three times for 10 
minutes with PBS-Tween and scan the blot with medium resolution on LiCor Odyssey 
Infrared Imaging System. Evaluate your data using the supplied application software.   
Incubate the membrane for 30 min with blocking solution, wash with PBS-T and incubate 
with a new primary antibody or dry the blot between two 3mm Whatman-sheets. 
2.4.6. Immunoprecipitation with crosslinked beads 
In order to use equal amounts of whole cell protein for the immunoprecipitation, equilibrate 
the native yeast lysates to equal concentrations with IP-buffer plus protease inhibitors and add 
500µl of the dilution to 40 µl of anti-HA (12CA5) antibody cross-linked to BSA-coated 
protein A sepharose beads (1:1 suspension in PBS) and incubate for 1 hour, rocking, at 4°C.  
Then centrifuge the mixture for 1 minute at 1000 rpm (Eppendorf centrifuge 5417C). 
Carefully remove the supernatant. Wash the beads once with IP-buffer supplemented with 
protease inhibitors, three times with cold TBS. After the final centrifugation, carefully remove 
the supernatant. Use the immunoprecipitates for protein phosphatase assays or boil the beads 
directly in 60µl minimum 1X GSD for 5 min at 95°C, if they are used for SDS-PAGE. Before 
loading the sample on a SDS-polyacrylamide gel, boil the samples again for 5 minutes and 
centrifuge for a few seconds at maximum speed. 
2.4.7. Protein phosphatase assays 
To determine catalytic activity of PP2A complexes from mammalian cells, immunoprecipitate 
similar amounts of HA-tagged C subunit and resuspend the immunoprecipitate in 400µl cold 
TBS.  
To test the catalytic activity of PP2A complexes towards phosphorylase a transfer 100µl of 
the 400µl immunoprecipitate suspension to a new 1.5ml safelock tube containing 15µl 1:1 
protein A sepharose beads (in PBS). Centrifuge at 1000 rpm for 1 minute and remove the 
supernatant. Resuspend the beads in 40µl phosphorylase a buffer. To start the protein 
phosphatase reaction, add 20µl of the 
32
P-labeled phosphorylase a (approx. 40µM) to the tube. 
Vortex immediately and incubate the reaction in a heating block for 15 min at 30°C, shaking. 
Stop the reaction by adding 180µl cold 20% TCA. Vortex the tube and place on ice for at 
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least 10 min. Centrifuge the tube at 14000 rpm for 10 min at 4°C. Transfer 200µl of the clear 
supernatant to a scintillation vial containing 5ml Ecosint H (National Diagnostics) and 
determine the amount of radioactivity released in the assay as 
32
Pi  in a scintillation counter. 
Spin the remaining part of the immunoprecipitate at 1000 rpm for 1 minute and remove the 
supernatant. Boil the beads in at least 60µl 1X GSD for 5 minutes at 95°C. Analyze the 
sample by SDS-PAGE and immunoblotting to determine the amount of catalytic subunit used 
in the phosphatase assay. 
2.4.8. ß-galactosidase-assay 
The amount of ß-galactosidase expressed, can be assayed by measuring hydrolysis of the 
chromogenic substrate, o-nitrophenyl-ß-D-galactoside (ONPG) as shown below (Miller, J. 
1972. Experiments in Molecular Genetics, p. 352-355. Cold Spring Harbor Laboratory, NY). 
 
Cell lysis 
Cells are washed with basic buffer. 100µl basic buffer/6-well are added, cells are scraped off 
with a rubber scraper and transferred to a 1,5ml tube. Cells are lysed by two consecutive 
freeze/thaw cycles in liquid nitrogen, with thawing them the first time at room temperature 
and the second time on ice. Then the lysate is centrifuged for 10minutes at 14000rpm at 4°C. 
The supernatant is transferred to a 1ml tube. Protein concentration is measured according to 
the protocol above. 
ß-galactosidase assay 
270µl ß-galactosidase assay buffer are mixed with 30µl protein lysate. According to the 
expected signal, different amounts of protein are used for the assay. Different liquid levels are 
filled up to 30µl with basic buffer. 
In order to avoid different starting time points, the lysates are pipetted onto the cap of the tube 
and then centrifuged down. 
The reaction mix is incubated for 1hour at 37°C at 400rpm. Stop the reaction by adding 500µl 
1M Na2CO3. Absorbance is measured at OD420. To compare signals, OD420 per µg whole cell 
lysate used, is calculated. 
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3. RESULTS 
3.1. Inducible RNAi 
A shRNA sequence (shPTPA1) targeting PTPA was established by Fellner et al. to transiently 
knock-down PTPA in HeLa cells (Fellner et al., 2003). As this sequence targets a sequence in 
the ORF of PTPA that is 100% identical between mouse and human, it was considered to be 
also functional in mouse cells. To determine the functionality of this sequence in mouse N2a 
cells, cells were transfected with either the constitutive pSUPER vector expressing a hairpin 
with a 19bp targeting sequence for the PTPA mRNA or the empty vector (pSUPER; 
Brummelkamp et al., 2002). HeLa cells were used as a positive control. As transient 
transfection of cell never reaches 100%, we selected transfected cells in order not to 
underestimate the effects of the siRNA. Geneticin selection takes about 7-10 days to kill all 
non-transfected cells. In contrast to that, selection with puromycin kills 99% of all non-
transfected cells within 2 days. Therefore we co-transfected a vector coding for the expression 
of the puromycin resistance gene in a ratio of 1:5, to be able to analyze the effect of the 
shRNA in a short timeframe. 24 hours after transfection, puromycin was added to the cells. 
Less than 5% of wild-type PTPA levels could be detected in lysates of both cell lines 4d post 
transfection of the shPTPA construct (Fig.1), indicating functionality of the knock-down 
construct in N2a cells.  
 
Fig.1: Downregulation of PTPA in N2a and HeLa cells, transfected with pSUPER-shPTPA1 
 
N2a and HeLa cells were co-transfected with the pNTO
Puro
 vector (see attachment for map) containing the 
coding sequence of the puromycin resistance marker and either empty pSUPER vector (pSUPER) or pSUPER-
shPTPA1, containing PTPA-targeting sequence# 1 (shPTPA1). After transfection cells were grown in medium 
supplemented with puromycin for 48h. Whole cell lysates were analyzed by SDS-PAGE and immunoblotting 
with anti-PTPA and ß-Actin (loading control) antibody. (n=1) 
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Studying the phenotypic appearance of the cells after 48h of puromycin selection we could 
observe rounded cells, apoptotic bodies and surface blebbing with some cells. However these 
cells were easily detached by rinsing the plate and therefore were considered to be apoptotic, 
because of a lack of puromycin-resistance. As there were viable cells visible, it was 
concluded, that there was no apoptotic effect of PTPA knock-down in these cells.  
Attempts to isolate transfected cells by co-transfection with a vector coding for the expression 
of green fluorescence protein (GFP) and sorting by fluorescence activated cell sorting (FACS) 
failed, because of low sorting efficiency due to a damaged laser.  
Next, the inducible vector pNTO, containing the sequence sh-PTPA1 was analyzed for its 
ability to knock down PTPA in N2a cells following the same protocol as above. Again HeLa 
were used as a positive control. N2a and HeLa cells were transfected with the pNTO vector, 
containing sh-PTPA1 (pNTO-shPTPA1) or a mismatch sequence, with changes from C to T 
at position 4 and from G to A at position 10 and 16 of the 19bp-sequence (pNTO-shControl-
1). Since there was no empty pNTO
Neo
 vector at hand, to be used as a negative control, cells 
were transfected with the empty vector pCI
Neo
. Again for selection of transfected cells, 
pNTO
Puro
 was co-transfected in a ratio of 1:5. 24 hours after transfection, puromycin was 
added to the cells. As the inducible vector was transfected into cell lines, that do not express 
the tet-repressor, no induction with Dox was needed for shRNA-expression. 
 
Fig.2: Downregulation of PTPA in N2a and HeLa cells, transfected with pNTO-shRNA1 
 
N2a and HeLa cells were transfected with empty pCI vector (pCI), pNTO-shPTPA1, containing PTPA-targeting 
sequence#1(sh-PTPA1) or pNTO-shControl1 containing the corresponding mismatch sequence (see attachment 
for maps). 
Again some of the cells displayed a phenotype similar to apoptotic cells, yet again these cells 
could easily be detached from the plate and therefore was probably due to the puromycin 
selection. 
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In contrast to the cells transfected with the mismatch control pNTO-shControl1, pNTO-
shPTPA1 transfected cells showed significant knock-down of PTPA, indicating that the 
vector system and sequence can be used for the establishment of stable knock-down cell lines 
(Fig.2).  
3.1.1. Testing of sequences targeting the 3`UTR of PTPA  
In addition to sequence shPTPA1, two new PTPA targeting sequences from the entire PTPA 
including the 5' and 3' untranslated regions were designed and tested for their ability to induce 
knock-down of PTPA. The 5' and 3' untranslated regions were chosen as possible 
phonotypical effects of PTPA knock-down could easily be controlled by a rescue experiment 
with a wild-type cDNA copy of PTPA.  
To evaluate the capacity of the newly designed shRNAs targeting the 3´UTR of PTPA to 
knock-down PTPA, N2a cells were transfected with the pNTO vector, containing sh-PTPA2 
or 3 (pNTO-shPTPA2/3) or a corresponding mismatch sequence (pNTO-shControl-2/-3) or 
the empty vector pCI
Neo
. For selection of transfected cells, pNTO
Puro
 was co-transfected in a 
ratio of 1:5. 24 hours after transfection, puromycin was added to the cells. 
Sequence sh-PTPA1 (pNTO-shPTPA1) and corresponding mismatch control were used as a 
positive and a negative control. 
A 60 and 67% knock-down could be detected in lysates 4d post transfection of the shPTPA2 
and shPTPA3 construct, respectively. While levels were unchanged in shControl-3 transfected 
cells, levels of shControl-2 transfected cells were reduced to less than 70% (Fig.3). 
Consequently, significant knock-down was achieved in shPTPA1, shPTPA2, shPTPA3 
transfected cells, when compared to the respective shControl and to wt-PTPA levels. 
Nevertheless, shControl-2 also induces a significant knock-down, therefore shPTPA1 and 3 
were used to produce stable PTPA knock-down cell lines. 
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Fig.3. Testing of different shPTPA constructs 
N2a cells were transfected using the same protocol as above, with either empty pCI vector (vector), pNTO-
shPTPA1-3 (sh-PTPA1-3) or pNTO-shControl1-3 (sh-Control 1-3). 
(A) Whole cell lysates were analyzed by SDS-PAGE and immunoblotting with anti-PTPA and ß-Actin (loading 
control) antibody. (B) Densiometric quantification of PTPA knock-down; the values are presented as a 
percentage of the PTPA expression level in control vector transfected N2a, which was set 100%. (n=5; mean 
±S.D.) Data were analyzed using the Student t-test. Differences with p-values less than 0.05 were considered 
statistically significant: 
(shPTPA1 p=3*10-4; shControl-1 p=0,6; shPTPA2 p=3*10-4; shControl-2 p=0,03; shPTPA3 p=3*10-4; 
shControl-3 p=0,7) 
3.1.2. Cloning of RNAi-insensitive PTPA for rescue experiments 
It is important to determine whether the phenotype of knocking-down PTPA in cell lines is 
due only to loss of PTPA function and not to possible RNAi-off-target effects. Therefore, 
rescue experiments with RNAi-insensitive PTPA have to be performed. For sequence 
shPTPA3, the ORF can be used directly for the rescue expression whereas with shPTPA1 
targeting the coding region this sequence has to be replaced in the ORF with a wobbled 
sequence to be refractory to the shRNA. Therefore PTPA was mutated by site-directed PCR-
mutagenesis (see materials and methods).  
Mutated PTPA was cloned into the vector pcDNA3_mmPTPA and sequenced. The sequence 
proofed to be correct. 
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3.2. Generation of N2aTRex cell lines with inducible PTPA knock-
down 
N2aTRex cells were transfected with the pNTO vector, containing shPTPA1, 3 or the 
corresponding mismatch control sequences shControl1/3 
For selection of transfected cells, cells were grown in medium supplemented with 600µg/ml 
geneticin for two weeks. Next, cells were seeded at clonal density and at least 10 single 
clones/shRNA were isolated. 
RNAi expression was induced with 1µg/ml doxycycline for 4 days. Whole-cell lysates were 
analyzed by SDS-PAGE and immunoblotting for PTPA knock-down.  
For shPTPA3 out of 10 clones, none showed considerable knock-down of PTPA. For 
shPTPA1, three out of 14 clones showed significant knock-down of PTPA upon induction 
with doxycycline. This knock-down was demonstrated in at least three independent 
experiments.  
However, in all three clones, continuously proliferating in culture or stored in liquid nitrogen 
and recultivated, the ability to inducibly knock-down PTPA got lost over a period of 4 weeks 
(Fig.4), probably due to counterselection or epigenetic silencing of the knock-down construct. 
 
Fig.4: Loss of PTPA knockdown in N2aTRex cells stably transfected with pNTO-shPTPA1 
 
N2aTRex14 cells were transfected with the pNTO vector containing shPTPA1. After single clone isolation, this 
clone showed significant PTPA knockdown after induction with doxycycline (Dox). 4 weeks later, no knock-
down could be induced. 
 
An explanation for this could be that the system is leaky, which means, that PTPA-targeting 
RNAi is constitutively expressed at low levels. As knock-down of PTPA causes apoptosis in 
HeLa cells (Fellner et al., 2003), this could lead to a clonal evolution towards a cell with 
decreased ability of PTPA knock-down, e.g. by silencing of the coding sequence for the 
shRNA.  
In order to avoid repeated loss of knock-down, the reason for loss of PTPA knock-down was 
analyzed: 
RNAi expression in the absence of doxycycline can be induced by two factors. First, leakiness 
of the H1TO promoter in N2aTRex14 cells can be caused by either low expression level of 
tetracycline repressor (tet-repressor) or by low affinity of the repressor to the operator. 
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Although a wt-repressor was initially introduced into N2a cells to produce the TetR 
expressing N2Trex cell lines, a mutation could have happened during the selection process 
and accidentally picked by choosing N2aTRex14. Second, the FCS used could contain 
tetracycline, thereby activating the expression of shRNA and thus the knock-down of PTPA 
which is harmful to the cells. 
3.2.1. Inducible Promoters in N2aTRex14 cells 
To analyze, if the TetR would be able to block expression of shRNA in the absence of the 
inducer, N2aTRex14 cells, were compared with three other cell lines expressing the tet-
repressor: HeLaTRex, HEK293TRex and Pc12TRex (kindly provided by S. Strack). 
To test for leakiness, activity of a tetracycline-inducible ß-galactosidase (ß-Gal), was 
compared in Dox-treated and untreated populations of these four cell lines. 
The cell lines were transfected with 0,5µg-8µg of the vector pcDNA5/TO-LacZ. 24 hours 
after transfection, cells were split and one half induced with doxycycline. After 24 hours of 
induction, whole cell lysates were analyzed for expression of ß-Gal. As a control for 
transfection efficiency and as a negative control cells were co-transfected with pCRUZ-GFP, 
coding for the expression of GFP. 
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Fig.5 A-D. Leaky expression of ß-Gal in different cell lines 
 
HEK293TRex, HeLaTRex, N2aTRex and Pc12TRex14 were transfected with 0,5-8µg of the vector 
pcDNA5/TO-LacZ (see attachment for map), where the reporter construct ß-Gal is under the control of a tet-
inducible promoter. 24 hours post transfection, cells were split and half of them induced with doxycycline for 24 
hours.  
After 24 hours of induction, whole cell lysates were analyzed for the expression of ß-Gal. Data are presented as a 
function of ß-Gal activity (OD420*10.000/µg protein) versus µg vector transfected.  
(n=3) 
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Fig.5E: Leaky expression of ß-Gal in N2aTRex cells 
 
N2aTRex14 were transfected with 0,05-1µg of the vector pcDNA5/TO-LacZ, to show that difference in leaky 
expression is not due to out titration of the TetR due to higher transfection efficiency. Data are presented as a 
function of ß-Gal activity (OD420*10.000/µg protein) versus µg vector transfected (n=3) 
 
Cell lines HEK293TRex, HeLaTRex and Pc12TRex showed no or very low leaky expression 
of ß-Gal even with high amounts of vector transfected (Fig.5A, B and D). The ß-Gal activity 
of induced cells in HEK293TRex cells increased about of 86 times, in HeLa cells about 51 
times and in Pc12TRex cells about 17 times, when compared to uninduced cells. 
Interestingly, the cell line N2aTRex14, exhibited high leaky expression, increasing with the 
amount of vector transfected (Fig. 5C). Inducibility (signal of induced cells/signal of 
uninduced cells) of the ß-Gal expression increased only 2-fold independent of the amount of 
DNA transfected. 
Yet, the overall ß-Gal activity/µg DNA transfected is higher in the cell line N2aTrex14 
compared to the other two, which was most probably due to higher transfection efficiency in 
N2aTRex14. Considering the transfection efficiencies, which were 81% in N2aTRex14, 26% 
in HeLaTRex and 46% in HEK293TRex on average, these differences adjust to the same 
level of ß-Gal expression in the three cell lines.  
As higher amounts of the vector could possibly outtitrate the tetracycline-repressor, and 
therefore be the cause for low inducibility of ß-Gal expression in N2aTRex14 cells, the 
experiment was repeated with lower amounts of DNA, from 0,05µg to 1µg DNA. Even then, 
the inducibility of expression stayed low at about 2-fold (Fig.5E). 
This becomes even more obvious when comparing absolute ß-Gal activity levels: 
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Both Hek293TRex and HeLaTRex cells show very low leaky ß-gal activity of about 1,2 when 
their induced ß-Gal activity was at about 40. In contrast to that, the N2aTRex cell line shows 
leaky ß-Gal activity of 12 when exhibiting an even lower induced ß-Gal signal of 30. 
This suggested that leakiness of this system is not due to a low expression of the tet-repressor, 
but rather to a less tight tet-promoter in N2aTRex14 cells, compared to others. This was 
confirmed by the fact, that N2aTRex14 cells expressed even higher amounts of tet-repressor 
than the cell line HeLaTRex (Fig.6). 
  
Fig.6: Comparing tetracycline-repressor expression of different cell lines 
 
(A) Expression levels of tetracycline-repressor in N2aTRex, HeLaTRex and HEK293TRex were analyzed by 
SDS-PAGE and immunoblotting with anti-tetracycline-repressor (TetR) and ß-Actin (loading control) antibody. 
N2a and HeLa cells were used as negative controls. (B) Densiometric quantification of tetracycline expression in 
N2aTRex, HeLaTRex and HEK293TRex. The values are presented as a percentage of the tetracycline-repressor 
expression level in HeLaTRex cells, which was set 100%. (n=1) 
 
To confirm the leakiness using another system, different cell lines stably expressing the tet-
repressor were transfected with a vector (pcDNA5/TO/HA-CSU, see attachment for cloning 
strategy), coding for a Dox-inducible HA-tagged C subunit of PP2A. 24 hours after 
transfection, cells were split and one half was induced with doxycycline for another 24 hours. 
Immunoblotting after 24 hours of Dox-stimulation indicates again that N2aTRex14 possesses 
a high expression level, even in the absence of doxycycline, whereas the other cell lines 
robustly repress transgene expression in the absence of doxycycline (Fig.7). 
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Fig.7: Leaky expression of different tet-repressor expressing cell lines in a pol III promoter based system  
 
N2aTRex, HeLaTRex, HEK293TRex and Pc12TRex were transfected with the vector pcDNA3/TO/HA-CSU 
(see attachment for map). Whole cell lysates after 24 h of doxycycline treatment were analyzed for expression of 
HA-tagged C subunit by SDS-PAGE and immunoblotting with anti-HA and anti-ß-Actin antibody (loading 
control). 
 
To summarize, the cell line N2aTrex14 showed high leaky expression, when compared to 
other tetracycline-repressor expressing cell lines. Of all cell lines, HEK293TRex exhibited 
least leaky expression and highest level of inducibility (81-fold). 
Thus, HEK293TRex were used as parental cell line for the generation of PTPA knock-down 
cell lines. The cell line HEK293TRex was transfected with the vector pNTO-PTPA1 or the 
corresponding mismatch control pNTO-Control-1. Cells were grown as single cells progeny 
in medium supplemented with geneticin for 2 weeks. RNAi expression was induced with 
1µg/ml doxycycline for 4 days and whole cell lysates were analyzed by SDS-PAGE and 
immunoblotting for PTPA knock-down.  
Out of 11 clones tested, 7 showed significant knock-down of PTPA to fewer than 50% upon 
induction with doxycycline: HEK293TRex14+pNTO-shPTPA1 clone #1,8,9,12,26,28,30 and 
29. Three of them with highest PTPA repression upon RNAi induction with doxycycline 
(HEK293-PTPA#1,8 and 9) are shown in Figure8. 
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Fig.8 Stable and inducible PTPA knock-down cell lines based on HEK293TRex cells 
 
HEK293TRex cells were transfected with the vector pNTO, containing the PTPA-targeting sequence#1 
(shPTPA1) and the corresponding mismatch sequence (shControl-1). 24hours post transfection cells were grown 
as single cells in medium supplemented with geneticin for 2 weeks. Single clones were induced for 4 days with 
doxycycline and whole cell lysates were analyzed by SDS-PAGE and immunoblotting with anti-PTPA and ß-
Actin (loading control) antibody (immunoblot done by Michaela Kugler). 
 
In addition, N2aTRex14 were also used for a new round of transfection and single-clone 
isolation with tetracycline-free FCS (see 3.2.2), as they are of neuronal origin and can be used 
in future to address the question of whether PTPA deregulation is involved in tau 
hyperphosphorylation and thus AD pathology.   
3.2.2. Analysis of non-approved-tetracycline-free FCS for presence of 
tetracycline 
One explanation for the observed loss of inducible PTPA knock-down in the previous 
functional PTPA-loss-of-function (PTPA-LOF) cells is, that RNAi expression in the absence 
of doxycycline was induced by tetracycline present in the not tetracycline-free approved FCS 
(non-approved FCS) used and because of this PTPA was suppressed even in the absence of 
Dox. The pro-apoptotic effect of PTPA suppression could act selectively on those cells, which 
able to knock-down PTPA and could thus drive a clonal evolution towards cells that lost their 
ability to knock-down PTPA. 
 
Differential proliferation of tetracycline-sensitive and /-resistant bacterial strains with 
increasing FCS-concentrations 
To address the question, whether there was tetracycline present in non-approved FCS, the 
proliferation rate of the tetracycline-sensitive bacterial strain HB-101 upon addition of FCS or 
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approved tetracycline-free FCS was analyzed. The strain Xl-1, which differs from HB-101 
among other things, in its tetracycline-resistance, was used as a control.  
For Xl-1 no difference in proliferation rate was detectable when adding 0-20% of either sera 
to the medium. Addition of 50% non-approved FCS and tetracycline-free FCS resulted in a 
decrease of proliferation rate to about 56% and 86%, respectively (Fig.9A). As there was no 
change in proliferation rate upon addition of tetracycline from 0-15µg/ml (Fig.9C), this 
change was most probably not due to tetracycline, but rather to an additional, unknown factor. 
This factor was capable to influence also the proliferation of Xl-1 negatively.  
Proliferation rate of HB-101 increased or stayed at 100% with rising concentrations up to 
25% of either sera, but then dropped down to 10% and 90% upon addition of 50% of non-
approved FCS and approved tetracycline-free FCS, respectively (Fig.9A). 
To determine the possible tetracycline-dependent effect on proliferation of HB-101, the effect 
of tet-free FCS was subtracted from the effect of non-approved FCS on proliferation. The 
resulting function is linear, as indicated by the applied trend line (Fig.9B). 
In contrast to that, addition of tetracycline to HB-101 led to an exponential decrease in 
proliferation rate (Fig.9C). 
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Fig.9 Proliferation rate of Xl-1 and HB-101 changed differentially upon incubation with increasing 
amounts of non-approved, tet-free FCS or tetracycline  
 
Both strains were grown in LB medium at 37°C for at least 7 hours. Proliferation of bacterial culture was 
quantified by measuring cell density at OD550 every hour. Proliferation constants were determined by calculating 
the slope in the linear range of a plot of time versus OD550 (proliferation curve). The values are presented as a 
percentage of the proliferation constant of bacteria, grown in 100% LB media, which was set 100%.(n=3; mean) 
(A) Both strains were grown in LB medium, supplemented with 0-50% non-approved or tet-free FCS. 
(B) Growth constants of HB-101 in non-approved FCS were adjusted, by subtracting the effect of tet-free FCS 
on the strain. The applied trend line shows, that the line has a linear form. 
(C) Both strains were grown in LB medium, supplemented with 0-15µg/ml tetracycline. 
Δ 
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To sum up, treatment with approved tetracycline-free FCS had, besides small differences, the 
same effect on both strains. Contrary to that, normal FCS had a different effect: Addition of 
50% FCS to the medium led to a 44% decrease in Xl-1 and a 90% decrease of proliferation in 
HB-101. So, there was a proliferation rate decrease, which seemed to be both tetracycline-
dependent and -independent. 
Proliferation rate of HB-101 dropped down to 10%, with 3µg/ml tetracycline added. 
Therefore, it could be argued, that in the medium, containing 50% non-approved serum, the 
same amount of tetracycline was probably present. However, this is in contrast to the fact that 
addition of 25% FCS to HB-101 did not lead to a decrease of proliferation to 25%, which 
could be expected if there were 1,5µg/ml tetracycline in the serum, but proliferation dropped 
down to only 80% (Fig.9B). Therefore it was concluded, that the observed decrease in 
proliferation of HB-101 with 50% non-approved FCS added was not only due to tetracycline, 
but rather to an additional factor present only in non-approved FCS. This is further supported 
by the fact that addition of increasing concentrations of non-approved FCS did not lead to an 
exponential, but to a linear decrease in proliferation rates. 
It was concluded, that this method was not appropriate to determine the levels or show 
existence of tetracycline in non-approved FCS. 
 
Differential induction of ß-galactosidase in tetracycline-inducible HEK293TRex cells 
upon addition of non-approved and approved tetracycline-free FCS 
In order to analyze the non-approved FCS for the presence of tetracycline, HEK293TRex 
cells were stably transfected with the reporter construct pcDNA6/TO-LacZ described above, 
to establish a cell line, which would allow the detection of tetracycline. 24hours post 
transfection cells were grown medium supplemented with geneticin for 2 weeks. Afterwards 
single clones were picked. 
As the level of tetracycline in the non-approved FCS is probably very low, we looked for a 
HEK293TRex/TO-LacZ clone with high expression levels of ß-galactosidase upon addition of 
doxycycline and very low expression in the absence of doxycycline/tetracycline, i.e. high 
inducibility. 
To do so, ß-Gal activity was analyzed in whole cell lysates of eight single clones, either 
induced with doxycycline or left uninduced (Fig.10A). 
Out of eight clones picked, clones #6 and #7 were chosen because of low background and 
high signal strength (Fig.10B). 
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Fig.10 Generation of a tetracycline-detection tool 
 
HEK293TRex cells were transfected with the vector pcDNA3/TO-LacZ, coding for the reporter protein ß-Gal 
under the control of a tet-inducible promoter. After transfection, cells were grown in medium supplemented with 
600µg/ml geneticin for 2 weeks and single clones were picked. After induction of ß-Gal expression with 10
-6
 
g/ml doxycycline in clones 1-8 for 24hours, whole cell lysates were analyzed for ß-Gal expression by a ß-Gal 
assay. 
(A) ß-Gal expression (arbitrary units) in single clones HEK293TRex-TO-LacZ#1-8 in the uninduced state (-
Dox) and induced state (+Dox). Clone#1, 3 and 7 showed highest ß-Gal expression level upon treatment with 
doxycycline. 
(B) Inducibility of HekTRex/TO-LacZ clones #1-8 was derived by calculating signal ratio of induced 
cells/uninduced cells. Clones #6 and 7 showed highest inducibility  
 
Next, HEK293TRex/TO-LacZ clone #6 and  #7 (HekTRex/TO-LacZ#6/7) were further 
characterized by inducing the cells with 10
-6
-10
-15 
g/ml doxycycline and measuring ß-Gal 
activity in whole cell lysates after 24 hours of induction.  
To ensure an excess of substrate, compared to amount of enzyme, 2µg whole cell lysate were 
used from cells induced with doxycycline-concentrations from 10
-6
-10
-9 
g/ml. To be able to 
detect subtle differences in signal strength in cells induced with 10
-9
-10
-15 
g/ml doxycycline, 
500µg whole cell lysate were used. 
The ß-Gal activity decreased with decreasing doxycycline concentrations from 10
-8 
to 10
-12
 
g/ml. From a doxycycline concentration of 10
-12
µg/ml only background signal was detectable 
(Fig.11 and 12).  
However, as can be seen in the flattening of the curve in Fig. 11, ß-Gal activity was 
underestimated in lysates of HEK293TRex/TO-LacZ#7 cells induced with 10
-6
 and 10
-7 
g/ml 
doxycycline by adding too less substrate to the reaction. The same is true for 
HEK293TRex/TO-LacZ#6 cells induced with 10
-6
 to 10
-8
 g/ml doxycycline. 
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Fig.11 Standard curve for ß-Gal assay in HEK293TRex/TO-LacZ#6 and #7 
 
Cells were grown in medium supplemented with 10% approved tetracycline-free FCS and incubated with 
doxycycline concentrations from 10
-6
-10
-15
g/ml. After 24 hours of doxycycline induction, whole cell lysates 
were analyzed for ß-Gal activity. The x-axis shows ß-Gal activity (arbitrary units), the y-axis shows the 
doxycycline concentration, cells were incubated with. (n=2; mean ±S.D.) 
 
To determine the presence and concentration of tetracycline in non-approved FCS, cells were 
grown in medium supplemented with non-approved FCS or approved tetracycline-free FCS as 
a negative control. After 24 hours of proliferation in the two different sera, cells were lysed 
and analyzed for ß-Gal assay activity. 500µg of whole cell lysate were used for one assay. 
There was a significant difference in ß-Gal activity between whole cell lysates of cells grown 
in approved tetracycline-free FCS or in non-approved FCS. While ß-Gal activity in cells 
grown in approved tet-free FCS was in the background range, ß-Gal activity of cells grown in 
non-approved FCS was in the range of 10
-10
µg/ml doxycycline (Fig.12). 
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Fig.:12 Non-approved FCS contained a tetracycline concentration equivalent to 10
-10
g/ml doxycycline 
 
ß-Gal signals of whole cell lysates of HEK293TRex/TO-LacZ#7 cells, induced with Dox concentrations from 
10
-9
-10
-15
g/ml were used to establish a standard curve. HEK293TRex/TO-LacZ#7 cells were grown in serum 
supplemented with either 10% approved tet-free FCS (tet-free FCS) or in non-approved FCS (FCS) for 24 hours. 
ß-Gal activity in whole cell lysates was compared to signals of the standard curve.  
Lysates of cells grown in approved tetracycline-free FCS showed no ß-Gal activity. But lysates of cells grown in 
non-approved FCS showed ß-Gal activity that resembled induction with 1x10
-10
 µg/ml doxycycline. 
 
This result was further confirmed by using the cell line HekTRex-LacZ#6. Consequently, for 
the next round of N2aTRex14 transfection with shPTPA and single cell isolation, approved 
tetracycline-free FCS was used. 
3.2.3. Generation of stable PTPA knock-down cell lines 
To generate stable PTPA knock-down clones, N2aTRex14 cells were co-transfected with the 
pCRUZ
Neo
-GFP vector containing the coding sequence of GFP and either the vector pNTO, 
containing the PTPA-targeting sequence#1 (shPTPA1) or the corresponding mismatch 
sequence (shControl-1). 24hours post transfection cells were GFP-sorted (FACS facility at the 
IMP) and grown as single cells progeny in medium supplemented with geneticin for 2 weeks. 
RNAi expression was induced with 1µg/ml doxycycline for 4 days and whole cell lysates 
were analyzed by SDS-PAGE and immunoblotting for PTPA knock-down.  
Three out of 90 clones tested, showed significant knock-down of PTPA upon induction with 
doxycycline (Fig.13):  
N2aTRex14+pNTO-shPTPA1 clone #18 and #30 (shPTPA#18/30) showed a 2,5x reduction 
of PTPA levels when induced with doxycycline. PTPA levels of N2aTRex14+pNTO-
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shPTPA1 clone #89 (shPTPA#89) showed a 3,8x reduction upon induction of shRNA 
expression with doxycycline (Fig.13). 
The ability to knock-down PTPA upon induction with doxycycline and the expression of GFP 
remained stable over at least three months. 
 
 
 
 
Fig.13 Stable and inducible PTPA knock-down cell lines 
 
N2aTRex14 cells were co-transfected with the pCRUZ vector containing the coding sequence of GFP and the 
vector pNTO, containing the PTPA-targeting sequence#1 (shPTPA1) or the corresponding mismatch sequence#1 
(shControl-1). 24hours post transfection cells were GFP-sorted and grown as single cells in medium 
supplemented with geneticin for 2 weeks. (A) Single clones were induced for 4 days with doxycycline and whole 
cell lysates were analyzed by SDS-PAGE and immunoblotting with anti-PTPA and ß-Actin (loading control) 
antibody. (B) Quantification of PTPA expression of the five cell lines. The values are presented as a percentage 
of the PTPA expression level in uninduced N2aTRex14, which was set 100%. (n=3; mean ±S.D.) 
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However, the pCRUZ-GFP vector, the cells were co-transfected with, contained the coding 
sequence for neomycin-resistance. The same resistance gene was also encoded on the shRNA-
expressing vector. 
This experimental error could have contributed to the low efficiency in the establishment of 
stable PTPA knock-down clones, as cells that have lost the vector pNTO-shPTPA could still 
be neomycin-resistant through retaining pCRUZ
Neo
-GFP. Additionally, GFP is under the 
control of the strong CMV promoter and high expression levels of GFP are known to have a 
toxic effect on the cells. Due to time constraints I was unable to repeat the generation of 
PTPA knock-down clones without the use of pCRUZ
Neo
-GFP vector. 
3.3. Effect of PTPA suppression on PP2A biogenesis in 
mammalian cells 
3.3.1. Analysis of the effect of PTPA knock-down on proliferation 
To examine the effect of PTPA loss on PP2A in more detail, we relied on these 3 clones. Cell 
lines N2aTRex14 (parental) and shControl1 (mismatch control) were used as controls.  
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Fig.14 Timecourse of PTPA knock-down and proliferation in PTPA knock-down and control cell lines  
 
1*10
5 
cells/plate were seeded and induced next day with doxycycline (+Dox). Un-/induced cells were counted 
(D), lysed on day0-4 and analyzed for knock-down of PTPA by SDS-PAGE and immunoblotting, using anti-
PTPA and anti-ß-Actin (loading control) antibody (A-E). 
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Fig.14 F-G: Timecourse of PTPA knock-down and proliferation in PTPA knock-down and control cell 
lines  
 
 Proliferation rate of cell lines upon doxycycline treatment, relative to uninduced cells 
 
Analysis of differences in cell proliferation upon induction of PTPA knock-down was 
performed two times with different results. 
In the first experiment cell proliferation upon induction of PTPA knock-down showed a 
reduction of proliferation rate to about 80% of the uninduced cells on day 4 and 5 upon 
doxycycline treatment for the two control cell lines, probably due to its cytotoxic effect 
(Fig.14F) (Ermak et al., 2003). 
On day4 of shRNA-induction, proliferation of shPTPA1#18 and #30 decreased to 65% and 
68% when PTPA- expression decreased to 87% and 70% respectively (Fig.14C, D and F). 
However, the conclusion that PTPA knock-down results in decreased proliferation was 
conflicted by the fact, there was only a slight decrease in proliferation to 66% in clone 
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shPTPA1#89, which shows the strongest decrease of PTPA levels – down to 24% compared 
to PTPA levels in uninduced cells. 
Nevertheless, cell proliferation upon PTPA knock-down in clone shPTPA #89 was reduced 
on day 5 to 29%, although PTPA levels did not change markedly from day4 to 5. Maybe the 
effect of PTPA suppression on cellular processes is delayed in time (Fig.13F). 
To summarize this experiment, a negative effect of PTPA suppression on cell proliferation 
could be observed for all shPTPA clones from day3 to day5. 
However, upon repetition of the experiment, such an effect on all cell lines could only be 
observed on day5 (Fig. 14G). 
Considering these slightly conflicting data and the fact, that this experiment was only repeated 
twice, we can only suggest, that it is probable that PTPA suppression has a negative effect on 
cell proliferation of these clones. In order to completely demonstrate this, this experiment 
needs to be repeated. 
3.3.3. Complex assembly in PTPA knock-down cells 
Although deletion of RRD1 and RRD2 in yeast results in a catalytic subunit with a 
conformation a decreased catalytic activity towards P-Ser/Thr, complex assembly is largely 
unaffected in these cells. To confirm these data in mammalian cells, first PP2A complex 
formation was assessed.  
Antibodies directed against the C subunit interfere with PP2A complex formation and thus 
cannot be used for the analysis. Therefore hemagglutinin (HA)-tagged C subunit was 
expressed in the PTPA knock-down clones. HA tagged C subunit cannot be expressed at 
unphysiologically high levels because a translational control mechanism adjusts the total C 
subunit amount to constant levels (Baharians and Schönthal, 1998).  
First, it was tested, how fast the expression level of HA-tagged C-subunit decreases after 
transient transfection and if thus would be affected by the suppressed PTPA levels. 
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Fig.15 HA-tagged C subunit expression decreased with time 
 
Analysis of the effect of PTPA knock-down on the rate of reduction of PP2A C subunit after transient 
transfection: 
shPTPA1#30 cells (A) and Control-1 cells (B) were seeded in a 6-well each and the cells of three wells of each 
6-well plate were induced. On three consecutive days after induction (day2-4), one well with uninduced cells and 
and one well with induced cells were transfected with the vector pcDNA3/HA-CSU (see attachment for map), 
coding for the expression of mammalian HA-tagged C subunit. On day5, whole cell lysates were tested for the 
expression level of HA-tagged C subunit by SDS-PAGE and immunoblotting 
 
As there was no difference in HA-CSU expression between uninduced and induced cells, it 
was concluded that induction of PTPA-knock-down has no effect on the C subunit expression 
of HA-tagged C subunit (Fig. 15A).  
shPTPA1#30 cells, transfected on day2 showed a low level of HA-CSU expression on day5, 
whereas cells transfected on day4, exhibited a high level of HA-CSU expression on day 5 (Fig. 
A,B). As the same effect was observed in a shControl-1 cell line, this effect was considered to 
be independent of the PTPA knock-down. This means, that the expression level of transiently 
transfected HA-CSU decreases with every day passing after transfection. 
So, two strategies were followed: PTPA knock-down clones were induced for three days and 
then transiently transfected or were stably transfected with the vector pcDNA3/HA-CSU. 
Using the first strategy, parental cell line N2aTRex14, mismatch control cell line shControl1 
and PTPA knock-down cell line shPTPA1#30 were stably transfected with empty vector 
pcDNA3 (pcDNA3) or vector pcDNA3/HA-CSU (HA-CSU). Cells were induced with 
doxycycline for four days. To determine whether loss of PTPA affects PP2A complex 
assembly, HA-tagged C subunit of PP2A was immunoprecipitated from lysates of untreated 
and doxycycline-treated cells. The immunoprecipitates were analyzed by immunoblotting for 
the presence of the A and various B-type subunits.  
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Fig.16 The heterotrimeric PP2A complex assembles correctly in PTPA knock-down cells 
 
(A) Parental cell line N2aTRex14, mismatch control cell line shControl1 and PTPA knock-down cell line 
shPTPA1#30 transfected with empty vector pcDNA3 (pcDNA3) or vector pcDNA3, coding for HA-tagged C 
subunit (HA-CSU). Cells were treated with doxycycline for four days. Whole cell lysates were analyzed for 
knock-down of PTPA by SDS-PAGE and immunoblotting. Blots were sequentially incubated with anti-HA, anti 
ß-Actin (loading control) and anti-PTPA antibody.  
(B) Anti-HA tag immunoprecipitates from lysates of parental cell line N2aTRex14, shControl1 and shPTPA1#30 
transfected with empty vector pcDNA3 (pcDNA3) or vector pcDNA3, coding for HA-tagged C subunit (HA-
CSU) were analyzed by 10%SDS-PAGE and immunoblotting. Blots were sequentially incubated with anti-HA, 
anti-A subunit, anti-B, B´ and B´´ antibody.  
 
PP2A complex assembly was not impaired in the parental and the mismatch control strain, but 
also not in the PTPA knock-down strain shPTPA1#30, which exhibited a PTPA knock-down 
to 50% of the PTPA expression level of the uninduced state of the cell line (Figure16).  
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3.3.4. Catalytic activity of mammalian C subunit in PTPA knock-
down cells  
The immunoprecipitates from cell lines either stably or transiently transfected with 
pcDNA3/HA-CSU, were further analyzed for catalytic activity towards the serine-14-
phosphorylated substrate phosphorylase a, a substrate that is dephosphorylated by all PP2A 
holoenzymes. This experiment was repeated only twice, one with transiently and once with 
stably pcDNA3/HA-CSU-transfected PP2A knock-down clones. 
Using cell lines stably transfected with the vector pcDNA3/HA-CSU, with a PTPA reduction 
to 50%, a reduction in catalytic activity of PP2A to 60% and 30% was shown in shPTPA1#30 
cells, compared to the parental and mismatch control cell line, respectively. However, 
catalytic activity of PP2A complexes isolated from induced PTPA knock-down strain 
shPTPA#30 was not different from the uninduced state (Fig.17A).  
However, different results were obtained for the cell line shPTPA1#89, transiently transfected 
with the vector pcDNA3/HA-CSU, when PTPA knockdown was already induced for three 
days to of 17% of the PTPA level in the parental cell line. 
A difference of 41% between the uninduced and the induced state of PTPA knock-down cell 
line shPTPA1#89 was shown. Nevertheless, an increase catalytic activity of PP2A to 166% 
and 125% was shown in shPTPA1#89 cells, compared to the parental cell line, probably due 
to experimental mistakes (Fig.17B). 
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Fig.17 Catalytic activity of the heterotrimeric PP2A complex is not altered in PTPA knock-down cells   
 
(A) Anti-HA tag immunoprecipitates from lysates of parental, mismatch control (shControl1) and PTPA knock-
down (shPTPA1#30) strains, stably transfected with pcDNA3/HA-CSU, either uninduced (-) or induced with 
doxycycline for 4 days (+) were analyzed by phosphatase assays toward the substrate phosphorylase a  
 (B) Anti-HA tag immunoprecipitates from lysates of parental and PTPA knock-down strain #89 (shPTPA1#89), 
transiently transfected with pcDNA3/HA-CSU either uninduced (-) or induced with doxycycline for 4 days (+) 
were analyzed by phosphatase assays toward the substrate phosphorylase a  
The assay values were normalized to the amount of the respective immunoprecipitated protein as determined by 
immunoblot analysis and are presented as a percentage of the activity for PP2A complexes purified from the 
wild-type strain, which was set 100%. 
 
However, this experiment was done only twice (once for each PTPA knock-down cell line) 
and needs to be repeated. 
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3.4. Effect of Bα-knock-down on differentiation of N2aTRex14 
N2aTRex were transfected with the vector pNTO
Puro
, containing shRNA targeting the PP2A 
subunit Bα (Bα-targeting sequence from Strack et al., 2004). Control cells were transfected 
with the corresponding mismatch sequence, followed by selection with 5µg/ml puromycin 
and single cell expansion. 
Out of 12 clones analyzed, 7 showed significant downregulation of the Bα subunit upon 
induction with doxycycline for three days. 
To analyze the effect of Bα-Knockdown on differentiation, knock-down was induced for 3 
days (day1-4) by supplementing 1µg/ml doxycycline.  
Bα -Knockdown was shown in whole-cell lysates prepared before and after differentiation 
(day 4 and day7), by SDS-PAGE and immunoblotting with anti-Bα and ß-Actin (loading 
control) antibody (Fig.18).  
     
 
Fig.18: Knockdown of PP2A-Bα by doxycycline-inducible shRNA 
 
(A) Protein levels of PP2A-Bα and Bδ in undifferentiated N2aTRex cells after 3d of doxycycline administration. 
Shown are 2 representative clones and a mismatch control. (B) Protein levels of PP2A-Bα in differentiated 
N2aTRex cells after 7d of doxycycline administration. (C) Quantification of Bα expression of the three presented 
cell lines; The values are presented as a percentage of the Bα expression level in uninduced shControl#4 cells, 
which was set 100%. (n=3; mean ±S.D.) 
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On day4, cells were seeded on poly-L-lysine. On day5 differentiation was induced by 
growing cells under starvation with low serum (1%FCS) or low serum plus 10µM retinoic 
acid (RA) for 48 hours. Pictures of cells are taken 24 and 48 hours after starting 
differentiation (day6 and 7, respectively). Differentiation state of cells is determined by 
comparing the number of cells with neurites longer than the cell axis (differentiated) to the 
total number of counted cells (differentiated and undifferentiated) (Fig.19A-F, Fig. 20A-F and 
Fig.21A-B) (for a complete experimental outline, see Fig. D in materials and methods).  
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Fig.19: Representative lightfield microscope pictures of neuronal differentiation of Bα-knockdown clones 
Bα-knockdown clones  
Expression of shRNA was induced for 3 days with 1 ug/ml Doxycycline (+Dox) (B, D, F) or cells were left 
untreated (A, C, E). Afterwards, differentiation was induced with low (1%FCS) serum for 48 hours. 
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Fig.20: Representative lightfield microscope pictures of neuronal differentiation of Bα-knockdown clones 
Bα-knockdown clones  
Expression of shRNA was induced for 3 days with 1 ug/ml Doxycycline (+Dox) (B, D, F) or cells were left 
untreated (A, C, E). Afterwards, differentiation was induced with low (1%FCS) serum and retinoic acid (RA) for 
48 hours. 
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Fig.20: Uninduced (-Dox) Bα-knockdown clones shBα#2, shBα#7 exhibit faster differentiation, compared 
to differentiation upon Bα-knock-down induced by doxycycline (+Dox). 
 
No significant difference was detected in mismatch control strain shControl#4. Differentiation was induced by 
low serum (1%) or low serum +10µM retinoic acid (RA) for 24 hours (A) and 48 hours (B) 
Shown are means ± S.D. from four independent experiments. Data were analyzed using the Student t-test. 
Differences with p-values less than 0.05 were considered statistically significant: 
(A) P-values, 24h differentiation: shBα#2/1% p=0,01; shBα#2/RA p=0,0001; shBα#7/1% p=0,098; shBα#7/RA 
p=0,025; shControl#4/1% p=0,82; shControl#4/RA p=0,19; 
(B) P-values, 48h differentiation: shBα#2/1% p=0,013; shBα#2/RA p=0,012; shBα#7/1% p=0,027; shBα#7/RA 
p=0,0003; shControl#4/1% p=0,24; shControl#4/RA p=0,76; 
 
Differentiation of uninduced Bα-knockdown-clones shBα#2 and #7 was faster, compared to 
clones with Bα-knockdown induced with doxycycline. Mismatch control cell line 
shControl#4 exhibited no significant difference of differentiation upon treatment with 
doxycycline.  
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4. DISCUSSION 
The role of PTPA in the biogenesis of PP2A in mammalian cells 
In most cell types, PP2A is responsible for the majority of dephosphorylations. Due to its 
overwhelming importance for normal cell physiology, it is not surprising that malfunction or 
dysregulation of PP2A has been associated with a plethora of pathologies, ranging from 
neuronal diseases, like Alzheimer and Parkinson`s disease to cancer. Moreover, several 
viruses use PP2A to deregulate cellular pathways in the host, underscoring the general 
importance of PP2A in signal transduction (for a review see Jahnssens and Goris, 2001; 
Arroyo and Hahn, 2005). Thus, deepened understanding about the biology of PP2A is of high 
importance to define novel therapeutic targets. 
PP2A is a prime example for a multisubunit enzyme that obtains its substrate specificity by 
combining one out of only two different catalytic C subunits with a vast number of different 
regulatory subunits. This explains how one catalytic subunit can process the broad range of 
different PP2A-substrates with a high degree of specificity. Free non-complexed catalytic C 
subunit is known to harm cells, probably due to its unrestricted and unspecific activity 
(Ronne, Carlberg et al. 1991). Egon Ogris and colleagues demonstrated the synthesis of the 
catalytic subunit as a low-activity form in yeast that is fully activated only through interaction 
with Rrd (Fellner et al., 2003). 
Although it was shown that PTPA - the mammalian homologue of Rrd – can partially 
compensate for Rrd1/2 loss in yeast, direct evidence that PTPA fulfils the same function in 
mammals is still missing. Therefore the major goal of this work was to study the role of PTPA 
in the biogenesis of PP2A in mammalian cells. 
As suppression of PTPA via RNAi leads to apoptosis in HeLa cells (Fellner et al, 2003), we 
took advantage of a doxycycline-inducible knockdown construct to overcome this limitation 
and to be able to perform biochemical studies. 
Moreover, PP2A is the major phosphatase involved in modulating the phosphorylation status 
of tau, a microtubule-associated protein. Emerging evidence suggests that hypoactivity of 
PP2A results in hyperphosphorylated tau, which then accumulates to form neurofibrillary 
tangles, a histopathological hallmark of AD neurons (for a review, see Tian et al., 2002). As 
the upstream function of Rrd is crucial for the biogenesis of active and fully functional PP2A 
in yeast, E. Ogris and E. Sontag postulated that malfunction of PTPA could be causative for 
the observed PP2A deregulation in brains affected by AD. 
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To establish a possible functional link between PTPA activity and regulation of tau 
phosphorylation via PP2A, we selected the neuronal N2a cell line for PTPA loss-of-function 
approaches. 
Successful knockdown of PTPA was demonstrated elsewhere (Fellner et al, 2003). We cloned 
this targeting sequence into an inducible expression vector and were able to reproduce PTPA 
repression. In addition two other newly designed targeting sequences also displayed 
significant levels of protein knockdown if transiently transfected. 
To be able to perform complementation experiments we also established an RNAi-resistant 
form of PTPA, where single nucleotides of the coding sequence were substituted without 
changing the protein sequence. 
The neuronal N2a cells bearing the tetracycline-sensitive repressor were firstly chosen as the 
parental cell line for knockdown experiments, but showed very high leaky expression and low 
inducibility (factor 2) in my hands. Thus, I used HEK293TRex as an additional model. 
Although this cell line is not of neuronal origin, it is nevertheless very instrumental due to 
observed high inducibility (factor 86) and absence of leakiness. 
In a first attempt, I established 3 inducible knock-down N2a clones, able to suppress PTPA 
upon doxycycline treatment. This ability was lost over a period of 4 weeks, probably due to 
the presence of tetracycline in the FCS the medium was supplemented with. Tetracycline 
could activate the doxycycline-dependent expression of shRNA and thus the knock-down of 
PTPA constitutively, driving a selection for cells with decreased PTPA knock-down, e.g. by 
epigenetic silencing of the shRNA construct.  
Indeed, we could show the presence of 10
-10
µg/ml tetracycline in the FCS used. Using 
approved tetracycline-free FCS, we were able to generate three inducible PTPA knock-down 
clones that were stable over a period of at least three months. 
Interestingly, 2 of these 3 clones exhibited a 2 to 3-fold increase of proliferation rate in the 
uninduced state, when compared to the parental cell line (data not shown), probably due to an 
additional genetic event favoring proliferation/survival. This could involve either random or 
insertional mutagenesis due to incorporation of the shRNA transgene. Although no such 
increase of proliferation was shown in our third clone, the possibility of an additional genetic 
event seems likely, given that in total only three out of 90 clones tested were positive for 
inducible PTPA knock-down. Maybe an additional genetic insult is needed for N2aTRex to 
tolerate PTPA knock-down.  
Consistent with these observations, the yield of knockdown-proficient clones was much 
higher in HEK293TRex, which are devoid of leaky expression. 
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However, it is also likely, that the low percentage of PTPA knock-down clones in all stable 
neomycin-resistant clones is due to an experimental mistake , namely the co-transfection of 
these cells with the pCRUZ
Neo
-GFP vector, initially used to sort transfected cells, because 
both vectors coded for a neomycin-resistance gene and therefore the shPTPA-expressing 
vector could be lost without losing the resistance and high ectopic GFP-expression levels 
have been shown to have a toxic effect on cells.  
Therefore, the higher rate of HEK293TRex clones able to knock-down PTPA could be due to 
the fact, that these cells were not co-transfected with pCRUZ
Neo
-GFP. 
All three shPTPA clones based on the N2aTRex cell line were used to analyze proliferation 
rate, PP2A complex assembly and PP2A activity upon PTPA suppression.  
I could not detect a significant reduction of proliferation upon PTPA knock-down, also PP2A 
complex assembly seemed not to be compromised. Moreover, knockdown of PTPA to half 
the protein amount did not result in altered PP2A activity, as determined by phosphatase 
assays. With a reduction of PTPA to 17% only a small decrease in phosphatase activity could 
be detected. 
Taken together, this suggests that even low protein levels suffice to fulfill required functions. 
Additional studies in other cell systems are warranted to further elucidate these questions. 
Based on this study, the cell line HEK293TRex seems to represent a very promising model 
system to address the regulation of PP2A by PTPA. 
 
The role of PP2A regulatory subunit Bα in differentiation of neuronal cells 
The Bα-containing heterotrimer ABαC is the major phosphatase for tau and therefore 
involved in maintaining microtubule integrity. In this manner, Bα could be important in 
neuronal differentiation in addition to its general “housekeeping” functions, which are evident 
from its ubiquitous spatiotemporal expression 
In contrast to the A, C and Bα subunits, which show ubiquitous spatiotemporal expression 
patterns, the Bβ and Bγ subunits are differentially regulated. The latter two are detectable 
mainly in the brain and are subject to developmental regulation, with Bβ levels decreasing 
and Bγ increasing sharply after birth (Strack et al, 1998). This regulation suggests distinct 
functions of PP2A holoenzymes in brain development and functional maturation, depending 
on the included B subunit. 
I was interested whether the ubiquitous Bα subunit plays a role in the process of functional 
differentiation, which goes beyond its “housekeeping” phosphatase functions 
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Indeed, I could demonstrate a role for the Bα subunit of PP2A in this process, as 
differentiation induced by serum-starvation or retinoic acid was markedly reduced after 
RNAi-mediated Bα-knockdown in N2a cells. 
However, differentiation was reduced, but not abolished upon knockdown of Bα. This could 
be explained by functional compensation through Bβ and/or Bγ. In this respect, it is important 
to note, that Bγ was shown to co-localize with cytoskeletal substrates that are important in the 
establishment and maintenance of neuronal connections (Strack et al, 1998).  
Although – as mentioned above - some regulatory B subunits are expressed in a tissue- and 
developmental stage-specific pattern, any given mammalian cell is believed to express several 
dozen distinct PP2A heterotrimers formed by the combination of the 20 PP2A subunit genes. 
This complexity presents a considerable challenge, particularly because functional 
redundancy can complicate the interpretation of genetic ablation experiments.  
Further experiments using single and combined loss of different B subunit(s) are needed to 
conclude which one(s) are predominantly involved in neuronal differentiation during brain 
development. 
Furthermore microtubule (MT) destabilization is linked with a substantial number of diseases, 
including Alzheimer´s disease (reviewed in Mandelkow et al., 2003). An involvement of 
PP2A in this process is indicated by the fact that PP2A directly binds to and regulates MT 
dynamics and that down regulation of PP2A enzymes containing Bα subunit occurs in 
Alzheimer´s disease (Sontag et al., 1995, 1996, 1999, 2004; Merrick et al., 1997; Hiraga and 
Tamura 2000).  
Nunbhakdi-Craig et al. have found that silencing of the PP2A Bα subunit in N2a and NIH3T3 
cells is sufficient to induce breakdown of acetylated and detyrosinated MTs (Nunbhaki-Craig 
et al., 2007). Our results provide evidence for the importance of Bα for differentiation of N2a 
cells. As axon growth critically depends on stable microtubule assembly, they also support the 
hypothesis that reduced amounts of neuronal Bα-containing PP2A heterotrimers could 
contribute to MT destabilization in Alzheimer´s disease.  
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